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is in past years, this highlights article takes the place of the
ditor’s Page, and was assembled by the Associate Editors
ased upon the papers that they perceived had or would
ave the greatest impact upon cardiology. Space constraints
esult in omitting many excellent papers, and we apologize
n advance to the authors.
nterventional Cardiology
ong-term outcomes. A patient-level, pooled analysis of 4
andomized sirolimus-eluting stent (SES) trials (1) in 1,748
atients assigned to receive either an SES or bare-metal
tent (BMS) showed a continued benefit of SES on target
essel revascularization (TVR) (15.2% vs. 30.1%; p 
.0001) without differences in 5-year rate of death, myocar-
ial infarction (MI), the composite of death/MI, or stent
hrombosis (ST). The annualized rates of definite/probable
T after 1 year were 0.4% for SES and 0.2% for BMS. SES
ompared with BMS demonstrated superior 5-year reduction
f TVR without an increase in rates of death, MI, or ST.
ES in ST-segment elevation myocardial infarction
STEMI). A meta-analysis identified 13 randomized trials
n  7,352) comparing BMS versus DES in STEMI (2).
ver a 2-year follow-up, DES significantly reduced TVR
relative risk [RR]: 0.44), without increasing MI or ST.
imilarly, in 18 registry studies (n  26,521), DES signif-
cantly reduced TVR (RR: 0.54; 95% confidence interval)
ithout an increase in MI. Death was significantly lower
ith DES within 1 year of the index percutaneous coronary
ntervention (PCI), but there were no differences within 2
ears. The use of DES appears safe and efficacious in
atients with STEMI.
rom the *Cardiology Division, UCSD Medical Center, San Diego, California;
Leiden University Medical Center, Leiden, the Netherlands; ‡University of Min-
esota, Minneapolis, Minnesota; §Stanford University, Stanford, California; Veter-
ns Affairs Medical Center, San Diego, California; ¶Johns Hopkins Hospital,i
altimore, Maryland; #Department of Cardiology, Cleveland, Clinic; and **Pediatric
ardiology, Oregon Health and Science University, Portland, Oregon.ES in saphenous vein grafts (SVGs). Eighty patients
ith 112 lesions in 88 SVGs were randomized to a BMS or
aclitaxel-eluting stent (PES) (3). Binary angiographic re-
tenosis occurred in 51% of the BMS-treated lesions versus
% of the PES-treated lesions. During a median follow-up
f 1.5 years, the PES patients had less target lesion
evascularization (TLR) (28% vs. 5%) and target vessel
ailure (46% vs. 22%), and a trend toward less TVR (31% vs.
5%). In SVG lesions, PES are associated with lower rates
f angiographic restenosis and target vessel failure than
MS.
oronary artery disease. A total of 130 patients with
ignificant proximal left anterior descending coronary artery
LAD) coronary artery disease were randomized to either
ES (n  65) or minimally invasive direct coronary artery
ypass (MIDCAB) surgery (n  65) (4). Major adverse
ardiac events (MACE) at 12 months occurred in 7.7% of
ES patients versus 7.7% after MIDCAB (p  0.03 for
oninferiority). Although noninferiority was observed in
eath and MI, noninferiority was not established for the
ifference in TVR (6.2% vs. 0%, noninferiority p  0.21).
linical symptoms improved significantly in both treatment
roups. In isolated proximal LAD disease, SES is noninfe-
ior to MIDCAB surgery at 12-month follow-up with
espect to MACE at a similar relief in clinical symptoms.
oronary vasoconstriction. Coronary endothelial dys-
unction was evaluated in a randomized fashion at 6 months
ollowing LAD implantation of zotarolimus-eluting stent
ZES) (n  20), SES (n  20), and BMS (n  10) (5).
ncremental intracoronary acetylcholine (Ach) and nitrate
nfusions were given and coronary diameter evaluated in the
-mm segments proximal and distal to the stent. In the
ES groups, more intense vasoconstriction was observed at
-month follow-up than before stenting. Endothelial func-
ion associated with BMS was most preserved, whereas
esponses to ZES were more preserved compared with SES.
his study suggests that long-term vasomotor responses
iffer by stent type, and this may have clinical implications
n explaining recurrent symptoms in some patients follow-
ng DES.
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January 26, 2010:380–407 Highlights From JACC 2009escue PCI. The long-term outcomes of rescue PCI was
eported in the REACT (Rescue Angioplasty Versus Con-
ervative Treatment or Repeat Thrombolysis) trial, which
ad shown a significant 6-month benefit favoring rescue
CI following failed thrombolytic therapy (6). One-year
vent-free survival for patients randomized to rescue PCI
as 81.5%, compared with 64.1% for repeat thrombolysis
nd 67.5% for conservative therapy (p  0.004). Adjusted
azard ratio (HR) for a median of 4.4 years for overall
ortality for rescue PCI was 0.41 versus repeat thrombol-
sis and 0.43 for rescue PCI versus conservative therapy. An
ccompanying meta-analysis (7) of 6 trials addressing this
ssue pooling 908 patients showed a nonsignificant reduc-
ion in mortality (odds ratio [OR]: 0.74), although under-
owered. The authors suggested rescue PCI is the best
ption for failed thrombolysis.
tatins in PCI. In another study targeted toward assessing
he efficacy of acute statin therapy prior to PCI, Di Sciascio
t al. (8) implemented a reloading of atorvastatin just prior
o intervention. They randomized 383 patients to either an
torvastatin reload (80 mg 12 h before intervention, with a
urther 40 mg immediately pre-procedure), or placebo. All
atients had been on statin therapy prior to the intervention.
he primary end point (30-day incidence of MACE)
ccurred in 3.7% of patients who received the atorvastatin
eload and 9.4% in the placebo arm (p  0.03), driven
rimarily by reduction in periprocedural myocardial infarc-
ion. Multivariant analysis showed that atorvastatin reload
as a predictor of 30-day adverse events (OR: 0.50). In an
ccompanying editorial, Ellis and Anwaruddin (9) comment
hat based upon a large body of evidence, including the
RMYDA-RECAPTURE (Atorvastatin for Reduction of
yocardial Damage During Angioplasty) study, it seems
ndisputable that pre-treatment with statins benefits pa-
ients undergoing PCI, likely due to a pleiotropic effect of
he agents.
In the NAPLES II (Novel Approaches for Preventing or
imiting Events II) trial, (10) atorvastatin (80 mg, n 338)
ersus no statin treatment (control group; n  330) was
dministered the day before elective PCI in 668 statin-naive
atients. The incidence of a periprocedural MI was 9.5% in
he atorvastatin group and 15.8% in the control group. This
tudy expands the acute efficacy of high-dose statins to the
eriprocedural period and suggests a viable modality to
urther reduce the incidence of periprocedural MI in elective
CI.
egistry studies. Six large registry studies were published
valuating clinical outcomes in patients treated with DES
11). The Western Denmark Heart Registry demonstrated
n 2,395 consecutive patients followed up for 2 years that the
ncidence of definite ST was 0.64% in BMS, 0.50% in SES,
nd 1.30% in PES patients. The incidence of MI was 3.8%,
.1%, and 5.3% in BMS-, SES-, and PES-treated patients.
atients treated with PES had an increased risk of ST in the
-year follow-up period and mortality in the second year
ompared with those treated with BMS and SES. The wutch Stent Thrombosis Registry (12) documented in
1,009 patients treated with either a BMS or DES that 437
atients (2.1%) presented with a definite ST. A total of 140
Ts were acute, 180 were subacute, 58 were late, and 59
ere very late. Important correlates of ST were discontin-
ation of clopidogrel, undersizing of the coronary stent,
resent malignancy, and intermediate (50% to 70% )
oronary stenosis proximal to the culprit lesion. In the
CAAR (Swedish Coronary Angiography and Angioplasty
egistry) (13), 35,478 DES were implanted at 22,962
rocedures in 19,004 patients, and 1,807 restenoses were
eported over a mean 29 months follow-up. In diabetic
atients, the adjusted risk of restenosis was higher, and
estenosis was twice as frequent with the ZES than with
ther DES. Restenosis rate with PES was unrelated to
iabetes. Mortality did not differ between different DES.
Ko et al. (14) using propensity score matching analysis in
,944 off-label and 9,126 on-label PCI patients demon-
trated that for patients with off-label indications, rates of
VR at 3 years were significantly lower with DES com-
ared with BMS (11.6% vs. 15.3%, p  0.001). Mortality
ates were significantly lower among off-label patients
reated with DES compared with BMS at 3 years of
ollow-up (6.9% vs. 10.5%, p  0.001). For patients with
n-label indications, the use of DES was associated with
ignificantly lower rates of TVR, but composite rates of MI
r death were not significantly different from BMS. Data
rom the SCAAR registry (15) with a minimum follow-up
f 1 year and a maximum of 4 years showed no significant
ifferences between on-label DES and BMS (adjusted HR:
.02) or between off-label DES and BMS (adjusted HR:
.95) use with regard to the incidence of MI and death.
ff-label use of DES did not lead to significant differences
n the combined risk of death and MI compared with BMS
hroughout the whole spectrum of clinical indications.
Finally, the X-SEARCH (Xience V Stent Evaluated at
otterdam Cardiac Hospital) Registry (16) evaluated 649
onsecutive unselected patients treated with everolimus-
luting stents (EES) and 6-month clinical end points were
ompared with 3 historical cohorts. The EES group dem-
nstrated a higher incidence of all-cause mortality than the
ES group and a lower incidence of TVR than the BMS
roup. Multivariate adjustment demonstrated that BMS
as associated with higher TVR and MACE risk than EES
adjusted HR for TVR: 2.02; adjusted HR for MACE:
.15) that SES had a clinical outcome similar to that of
ES, and that PES had a higher risk of MACE than did
ES.
Due to the difficultly adjusting for confounding variables,
egistry studies should be considered hypothesis generating
n lieu of randomized controlled trials.
ntiplatelet and antithrombotic therapy. In the
ORIZONS-AMI (Harmonizing Outcomes With Revas-
ularization and Stents in Acute Myocardial Infarction)
rial, 3,602 patients with STEMI undergoing primary PCI
ere randomized to bivalirudin or unfractionated heparin
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Highlights From JACC 2009 January 26, 2010:380–407lus a glycoprotein (GP) IIb/IIIa inhibitor (17). Random-
zation was stratified by thienopyridine loading dose, which
as determined before random assignment. Patients in the
00-mg (n  2,158) compared with the 300-mg (n 
,153) clopidogrel loading dose group had significantly
ower 30-day unadjusted rates of mortality (1.9% vs. 3.1%,
 0.03), reinfarction (1.3% vs. 2.3%, p  0.02), and
efinite or probable ST (1.7% vs. 2.8%, p  0.04), without
igher bleeding rates. Compared with unfractionated hep-
rin plus a GP IIb/IIIa inhibitor, bivalirudin monotherapy
esulted in similar reductions in net adverse cardiac event
ates within the 300- and 600-mg clopidogrel loading
ose subgroups (p interaction  0.41). By multivariable
nalysis, a 600-mg clopidogrel loading dose was an
ndependent predictor of lower rates of 30-day MACE
HR: 0.72, p  0.04).
A substudy of the ACUITY (Acute Catheterization and
rgent Intervention Triage Strategy) trial (18) evaluated the
elative impact of spontaneously occurring and periproce-
ural MI on survival 1 year after PCI in 7,773 non-STEMI
atients. Periprocedural MI developed in 466 patients, and
pontaneous MI developed in 200 patients. Patients devel-
ping spontaneous and periprocedural MI compared with
hose patients without MI had significantly greater unad-
usted rates of mortality at 30 days and at 1 year. In a
ime-updated multivariable analysis, spontaneous MI was a
owerful independent predictor of subsequent mortality
HR: 7.49, p 0.0001), whereas periprocedural MI was not
significant predictor of mortality (HR: 1.30). This study
emonstrates that spontaneous MI unrelated to PCI is a
owerful predictor of subsequent mortality. In contrast,
eriprocedural MI is not an independent predictor of
ortality, but reflects baseline risk, atherosclerosis burden,
nd procedural complexity.
nprotected left main coronary artery (LMCA) inter-
entions. The ISAR-LEFT-MAIN (Intracoronary Stent-
ng and Angiographic Results: Drug-Eluting Stents for
nprotected Coronary Left Main Lesions) trial (19) ran-
omized 607 patients with symptomatic coronary artery
isease undergoing PCI for unprotected LMCA to PES or
ES. At 1 year, the cumulative incidence of death, MI, or
LR was 13.6% in the PES and 15.8% in the SES group
ithout a difference in definite ST (p  0.57). Mortality at
years was 10.7% in the PES and 8.7% in the SES group.
ngiographic restenosis was 16.0% with PES and 19.4%
ith SES (p 0.30). Implantation of either PES or SES in
nprotected LMCA lesions is safe and effective, and both of
hese DES provide comparable clinical and angiographic
utcomes.
In the LE MANS (Left Main Coronary Artery Stenting)
20) multicenter prospective registry of 252 patients under-
oing unprotected LMCA, DES were implanted in 36.2%
f patients. Major adverse cardiovascular and cerebral events
MACCE) occurred in 4.8% patients during the 30-day
eriod, which included 4 (1.5%) deaths. After 12 months,
here were 17 (12.1%) angiographically confirmed cases of Cestenosis. During long-term follow-up (mean 3.8 years)
here were 64 (25.4%) MACCE and 35 (13.9%) deaths.
he 5- and 10-year survival rates were 78.1% and 68.9%,
espectively. The DES lowered both mortality and
ACCE for distal unprotected LMCA lesions when com-
ared with BMS.
The multicenter, retrospective FAILS (Failure in Left
ain Study) registry of DES restenosis (21) in unprotected
MCA stenting showed that restenosis occurred in 70 of
18 patients (9.7%). Of these, 59 were treated percutane-
usly, whereas 7 patients underwent bypass surgery and 4
ere treated medically. In-hospital MACE included no
eriprocedural MI and only 1 death. Patients treated with
edical, interventional, and surgical therapy had the fol-
owing MACE rates, respectively: 50%, 25.4%, and 14.3%.
efinite, probable, and possible ST occurred in 0 (0%), 1
1.4%), and 1 (1.4%) patient, respectively. This study
uggested that DES restenosis in LMCA can be managed
ith a minimally invasive approach, achieving favorable
arly and late results.
The MAIN-COMPARE (Revascularization for Unpro-
ected Left Main Coronary Artery Stenosis: Comparison of
ercutaneous Coronary Angioplasty Versus Surgical Revas-
ularization) (22) Registry followed 858 consecutive pa-
ients with unprotected LMCA stenosis treated with SES
n  669) or PES (n  189) for 3 years. The adjusted risk
f death, MI, and TVR was similar among SES and PES.
he 2 groups also showed a comparable adjusted rate of
ach component of outcome: death (9.1% vs. 11.0%), MI
8.1% vs. 8.0%,), and TVR (12.1% vs. 10.6%). The 3-year
ates of definite or probable ST were 0.6% in the SES group
nd 1.6% in the PES group.
In view of the above and other recent studies in the
iterature, viewpoints have been proposed by several groups
o consider a revision of the guidelines for unprotected
MCA interventions (23,24). In particular, a JACC White
aper by Kandzari et al. (25) on behalf of the American
ollege of Cardiology (ACC) Interventional Scientific
ouncil reviewed the current evidence on unprotected
MCA PCI, and emphasized improvements in PCI tech-
iques in parallel with the benefits of DES to reduce clinical
estenosis. Clearly stating that ACC/American Heart As-
ociation (AHA) guidelines do not currently endorse PCI
or unprotected LMCA disease, they proposed future di-
ections and investigations to evaluate catheterization-based
reatment strategies as possible therapeutic options to by-
ass surgery.
ercutaneous valve. State-of-the art reviews by Piazza et
l. (26) on transcatheter mitral and pulmonary valve therapy
nd Zajarias and Cribier (27) on percutaneous aortic valve
eplacement brought the readers to the cutting edge of this
apidly evolving field.
tent fracture. Nakazawa et al. (28) performed a patho-
ogic assessment on stent fracture using high-contrast film-
ased radiographs of 177 consecutive lesions from the
VPath DES autopsy registry. Stent fracture was docu-
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January 26, 2010:380–407 Highlights From JACC 2009ented in 51 lesions. Sixty-seven percent of fracture lesions
ith a transection causing a gap in stent segment were
ssociated with adverse pathologic findings at fracture sites.
onger stent length, use of SES, and longer duration of
mplant were identified as independent risk factors of stent
racture by logistic regression analysis.
enal artery stenosis (RAS). Leesar et al. (29) investi-
ated the comparative accuracy of renal translesional pres-
ure gradients, intravascular ultrasound, and angiographic
arameters in predicting hypertension improvement after
tenting of RAS in 62 patients. A hyperemic systolic
radient 21 mm Hg provided the highest accuracy in
redicting hypertension improvement after stenting of
AS.
iacin and carotid atherosclerosis. Lee et al. (30) evalu-
ted the effects of nicotinic acid (NA) on progression of
therosclerosis and measures of vascular function in a
ouble-blind, randomized, placebo-controlled study of 2-g
aily modified-release NA added to statin therapy in 71
atients with low high-density lipoprotein cholesterol
HDL-C) (40 mg/dl) and either: 1) type 2 diabetes with
oronary heart disease (CHD); or 2) carotid/peripheral
therosclerosis. The primary end point was the change in
arotid artery wall area, quantified by magnetic resonance
maging (MRI), after 1 year. NA increased HDL-C by 23%
nd decreased low-density lipoprotein cholesterol by 19%.
t 12 months, NA significantly reduced carotid wall area
ompared with placebo (adjusted treatment difference:
1.64 mm2 [95% confidence interval: 3.12 to 0.16];
 0.03). In statin-treated patients with low HDL-C,
igh-dose modified-release NA, compared with placebo,
ignificantly reduces carotid atherosclerosis within 12
onths.
To further define the effectiveness of drug-eluting stents
ersus bare metal stents in real-world clinical practice,
ouglas et al. (31) examined the National Cardiovascular
ata Registry (NCDR) for the results of percutaneous
ntervention in their patients. They assembled data on an
xtraordinary number of variables in 262,700 patients from
52 NCDR sites and were able to assess outcomes including
eath, MI, revascularization, major bleeding, and stroke.
ES, implanted in 217,675 patients, had lower unadjusted
ates of death (12.9% vs. 17.9%), MI (7.3% vs. 10.0% of 100
atients), and revascularization (23.0% vs. 24.5% of 100
atients) than BMS implanted in 45,025. The benefit of
ES was observed in all subgroups and persisted through-
ut a 30-month follow-up. These data clearly support the
fficacy and safety of DES in Medicare-age patients.
cute coronary syndromes. Antithrombotic and anti-
latelet treatments, particularly in the setting of acute
oronary syndromes (ACS), continue to be areas of intense
esearch. Although fondaparinux in comparison to enoxapa-
in reduced major bleeding while preserving anti-ischemic
fficacy in the OASIS-5 (Fifth Organization to Assess
trategies in Ischemic Syndromes) study, whether this
dvantage extended to treatment with concomitant GP wIb/IIIa inhibitors or thienopyridines was unclear. In a
ubgroup analysis by Jolly et al. (32), there was a 40%
eduction in major bleeding with fondaparinux versus enox-
parin in the GP IIb/IIIa subgroup, as well as in those
eceiving thienopyridines, with similar rates of ischemic
vents. The authors conclude that the benefit of fondapa-
inux over enoxaparin extends to patients receiving both
hienopyridines and GP IIb/IIIa antagonists. The results
re particularly interesting, as in the ACUITY trial of
ivalirudin, that the reduced bleeding seen with bivalirudin
ersus heparin did not extend to the combination therapy
ith GP IIb/IIIa antagonists.
Similarly, Gurbel et al. (33) in the CLEAR PLATELETS-2
Clopidogrel with Eptifibatide to Arrest the Reactivity of
latelets) study, assessed the added effect of the GP IIb/IIIa
nhibitor eptifibatide when added to bivalirudin, both in the
resence and absence of clopidogrel pretreatment in 200
atients undergoing elective stenting. Both turbidometric ag-
regometry and thrombin-induced platelet fibrin clot strength
TIP-FCS) measured by thrombelastography were assessed.
latelet reactivity was significantly reduced by the addition of
ptifibatide. Those patients who had a periprocedural MI had
vidence of higher platelet reactivity.
The importance of bleeding in invasive cardiology has
eceived increasing attention in recent years. In an analysis
f the ACUITY trial, Nikolsky et al. (34) assessed the
ncidence and implications of gastrointestinal bleeding in
he setting of ACS. They found an incidence of 1.3%, with
ge, baseline anemia, longer duration of antithrombotic and
ntiplatelet agents treatment prior to angiography, diabetes,
moking, and greater ST-segment deviations as predictors
f gastrointestinal bleeding. On multivariate analysis, gas-
rointestinal bleeding was associated with mortality and
schemic complications, as well as ST. The importance of
reventing gastrointestinal complications of antiplatelet
gents has led to the frequent prescription of proton pump
nhibitors in conjunction with aspirin and clopidogrel. The
CLA (Omeprazole CLopidogrel Aspirin) study (35)
ighlighted the interaction of omeprazole and clopidogrel.
hether other proton pump inhibitors have a similar effect
as investigated by Cuisset et al. in the PACA (Proton
ump Inhibitors and Clopidogrel Association) study (36).
hey randomized 104 patients undergoing stenting for
cute coronary syndromes to omeprazole versus pantopra-
ole in addition to aspirin and clopidogrel. After a month of
reatment, platelet responsiveness to clopidogrel was supe-
ior in the group given pantoprazole with fewer nonre-
ponders (44% vs. 23%; p  0.04), suggesting the prefer-
ntial use of pantoprazole in the setting of clopidogrel
herapy.
The complexity of clopidogrel’s metabolism was further
mphasized in an analysis of the CLARITY–TIMI 28 (Clo-
idogrel as Adjunctive Reperfusion Therapy–Thrombolysis
n Myocardial Infarction 28) trial (37). Building on an
nitial report in the Journal in 2008 from Bliden et al. (38),
hich showed an association of cigarette smoking, a known
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Highlights From JACC 2009 January 26, 2010:380–407nducer of the cytochrome p450 system, with enhanced
esponse to clopidogrel, the authors examined the interac-
ion of clopidogrel and smoking in 3,429 STEMI patients
nd its impact on clinical outcomes. They found that
mokers (at least 10 cigarettes a day) had a particularly
nhanced benefit from clopidogrel (adjusted OR for a closed
nfarct-related artery or death/MI before angiography of
.49 compared with 0.72). The findings should, of course,
ot be seen as an endorsement of smoking but rather as
urther highlighting the importance of clopidogrel activa-
ion by the cytochrome system.
Clopidogrel initiation prior to early invasive management
s recommended by the ACC/AHA guidelines for ACS
atients, but is often withheld due to concerns that bleeding
ay occur if the patient is referred for coronary artery bypass
raft (CABG) surgery. In an analysis from the ACUITY
rial, Ebrahimi et al. (39) examined the outcomes in 1,539
atients who underwent CABG. They found a reduction in
schemic events (12.7% vs. 17.3%, p  0.01), without an
ncrease in bleeding. Importantly, in the trial, a 5-day
ashout period was recommended, and there was an in-
reased rate of transfusion in those that had early CABG
5 days) compared with those who had late CABG.
tress cardiomyopathy. Abraham et al. (40) describe a
ew variant of the Tako-tsubo syndrome involving 9 pa-
ients who developed transient left ventricular dysfunction
n the setting of epinephrine or dobutamine infusion. The
ndings are important in strengthening the evidence that
atecholamines are important in the pathogenesis of stress
ardiomyopathy, and also have implications in various
cenarios in which pressors are infused, such as post-surgery
nd in sepsis.
ypertension. The field of arterial stiffness has emerged as
entral to the understanding of hypertension as well as
ging. Protogerou et al. (41) evaluated 375 patients with
ypertension in the REASON (Preterax in Regression of
rterial Stiffness in a Controlled Double-Blind) study of
tenolol versus perindopril/indapamide. After a year of
reatment, those in the upper tertile of arterial stiffness had
he lowest response to therapy in terms of systolic blood
ressure control, independent of age, sex, mean blood
ressure, and cardiovascular risk factors. In an accompany-
ng editorial, Williams (42) highlights that subtle early
amage may set the stage for a vicious cycle in which
ncreasing arterial stiffness leads not only to more hyperten-
ion, but also to more stiffening of the aorta as the damage
ncreases. The superiority of central arterial pressure by
adial applanation tonometry rather than brachial pressure
n predicting cardiovascular outcomes was highlighted by
oman et al. (43) using data from the Strong Heart Study.
entral pulse pressure of 50 mm Hg or greater predicted
ardiovascular outcomes in both men and women.
Although data from randomized clinical trials have cast
oubt on the role of beta-blockers in the treatment of
ypertension, it has been assumed that they would have
articular utility in patients with increased heart rate. In an wnalysis of the ASCOT (Anglo-Scandinavian Cardiac Out-
omes Trial), Poulter et al. (44) showed that patients with
igher baseline heart rate still fared better with an
mlodipine-based therapy than an atenolol-based therapy.
avie, Messerli, and Milani, in an accompanying editorial
45) conclude that beta-blockers, particularly the nonvaso-
ilating beta-blockers, should not be used in the first-line
herapy of hypertension.
In an interesting analysis from the CAFE (Conduit
rtery Function Evaluation) substudy of the ASCOT trial,
illiams et al. (46) demonstrated that heart rate lowering
ith beta-blocker itself is inversely associated with central
ortic systolic and pulse pressures. The underlying mecha-
ism appeared to be increased wave reflection at lower heart
ates. That increased wave reflection is an important deter-
inant of increased pulse pressure and was further estab-
ished in a twin study from the United Kingdom by Cecelja
t al. (47). Focusing on women age 21 to 81 years, the
nvestigators determined that augmentation pressure, a
easure of wave reflection, was highly heritable and corre-
ates with the ratio of distal to proximal arterial diameters, a
easure of arterial dimension mismatch.
re-operative assessment. Randomized studies to date
ave not confirmed an advantage to routine angiography
rior to vascular surgery. Monaco et al. (48) studied 208
atients referred for major vascular surgery, with a Lee’s
evised cardiac risk index (RCRI) of at least 2, randomized
o angiography based on noninvasive testing versus routine
ngiography in all. The invasive strategy resulted in a
evascularization rate of 58.1% versus 40.1%. Major adverse
ardiovascular events were similar during the vascular sur-
ery hospitalization, but long-term survival and cardiovas-
ular events (at 58  17 months) were improved in the
roup that underwent routine invasive angiography. In an
ccompanying editorial, Landesberg and Mosseri (49) point
ut that more patients in the invasive group underwent
ABG, which while not statistically significant, may have
ed to better long-term outcomes. The lack of short-term
enefit supports the noninvasive approach as acceptable, but
he long-term benefit of the invasive approach highlights
he extensive overlap between peripheral arterial disease and
oronary disease.
In order to determine the effect of ramipril versus
osiglitazone in patients with impaired glucose tolerance or
mpaired fasting glucose, Lonn et al. (50) performed the
TARR (STudy of Atherosclerosis with Ramipril and
osiglitazone) by obtaining measurements of carotid medial
hickness by ultrasound. They randomized 1,425 patients
or follow-up of 3 years. The results showed that there were
o statistically significantly differences between ramipril or
osiglitazone and placebo patients with regard to the pri-
ary end point of maximal carotid intima-media thickness,
lthough there was a trend toward an improved outcome
ith rosiglitazone. The secondary end point of mean far
all left and right common carotid intima-media thickness
as significantly reduced by rosiglitazone. In an accompa-
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January 26, 2010:380–407 Highlights From JACC 2009ying editorial, Kaski and Cockerill (51) indicate that,
espite the beneficial actions of thiazolidinedione shown in
rior studies, the real beneficial effects of these agents
emain uncertain.
The role of bone marrow cell transplantation remains
ncertain. Yousef et al. (52) compared 62 patients with
cute myocardial infarction (AMI) who underwent intra-
oronary autologous bone marrow transplantation 7 days
fter AMI to 62 patients with comparable setting. Three
onths after bone marrow cell therapy, there was a signif-
cant improvement in ejection fraction and stroke volume
ndex in the treated patients, and infarct size was reduced by
%. In addition, decreases of normal heart rate variability,
ate potentials, and ectopic beats were observed in patients
eceiving the bone marrow cell therapy. Sixty months after
he therapy, the parameters initially observed were stable,
nd the exercise capacity of treated patients was significantly
ugmented in comparison with controls. Although a small
tudy, one of many, this long-term 5-year follow-up was
ncouraging in showing some suggestive evidence that bone
arrow cell transplantation may be of sustained benefit in
atients with AMI.
Prasugrel produced more active and consistent antiplate-
et effects compared with clopidogrel in the TRITON–
IMI 38 (Trial to Assess Improvement in Therapeutic
utcomes by Optimizing Platelet Inhibition with Prasugrel–
hrombolysis In Myocardial Infarction 38) (53). However,
he safety of a more effective oral antiplatelet regimen might
e compromised in the setting of GP IIb/IIIa inhibition. In
substudy from the TRITON–TIMI 38 trial, the greater
fficacy of prasugrel vs. clopidogrel was not diminished in
he presence of GP IIb/IIIa inhibition and bleeding risk was
ot increased with the combination of prasugrel and GP
Ib/IIIa inhibition. These findings suggest that prasugrel
an be safely administered to patients undergoing coronary
ntervention who receive GP IIb/IIIa inhibitors.
One of the major clinical applications for computed
omography (CT) angiography has been in the early triage
f patients with acute chest pain. Hoffmann and colleagues
eported the results of the ROMICAT (Rule Out Myocar-
ial Infarction Using Computer Assisted Tomography)
tudy in which they evaluated the use of CT angiography in
ow-risk patients with acute chest pain syndromes (54). A
otal of 368 patients were enrolled in this randomized
rospective trial, 81% of whom had either nonobstructive or
o coronary disease. Sensitivity and negative predictive
alues for ACS of atherosclerosis on CT angiography were
00%, but sensitivity of the presence of plaque for ACS was
nly 54%. Both the presence and severity of coronary plaque
ndependently predicted ACS and was incremental to the
hrombolysis In Myocardial Infarction risk score. In an
ccompanying editorial, Hlatky (55) opines that CT an-
iography in low-risk patients with chest pain in the
mergency department is a promising technique. However,
e points out that it remains to be documented whether this
echnology will result in improved outcomes. fypertrophic cardiomyopathy. This year, we had a focus
ssue devoted to hypertrophic cardiomyopathy. Maron et al.
56) provided a prospective on the 50-year history of left
entricular outflow obstruction in hypertrophic cardiomy-
pathy. They indicate that despite the many debates over
he years, data now unequivocally support the presence of
ubaortic obstruction as true impedance to left ventricular
LV) outflow, and provides a target for suitable therapy. In
n accompanying article, Bos et al. (57) discuss the diag-
ostic, prognostic, and therapeutic implications of genetic
esting for hypertrophic cardiomyopathy. They indicate that
his is a rapidly evolving area with nearly 20 susceptibility
enes having been identified. They point out that the
revalence of hypertrophic cardiomyopathy among patients
ith the 9 associated myofilament-encoding diseases is 35%
o 65%. Prognostic information is evolving from these
arious genes, and the potential role in screening families is
iscussed. At the current time, it is clear that the genotype/
henotype correlations are essential.
The outcome of patients with mildly symptomatic or
symptomatic obstructive hypertrophic cardiomyopathy has
een uncertain. Sorajja et al. (58) evaluated 544 consecutive
dult patients who were free of severe cardiac symptoms and
ere followed for a median of 9 years. They observed that
hese patients have only a slightly excess mortality, although
atients with markedly elevated resting outflow track gra-
ients were at high risk of heart failure or death.
eart Failure
here has been a lack of clarity about whether or not
eta-blockers should be withheld from patients with aortic
egurgitation. Sampat et al. (59) reviewed the records of a
roup of 756 patients with aortic regurgitation and related
he survival rate to beta-blocker therapy. Over a mean
ollow-up of 4.5 years, they found that beta-blocker therapy
as associated with significantly higher 1- and 5-year
urvival rates, even after adjusting for potential confounders.
urvival benefit was also seen when the investigators per-
ormed a propensity score analysis. In an accompanying
ditorial, Elkayam (60) noted many patients with aortic
egurgitation are candidates for beta-blockers based on the
resence of other conditions. He concluded that although
he results from this study should be considered to be
ypothesis generating, recommendations not to use beta-
lockers in aortic regurgitation should be removed.
To help further define the role of beta-blockers in the
reatment of patients with heart failure with preserved
jection fraction (HFPEF), van Veldhuisen et al. (61)
eported the results of a pre-specified analysis of the
ENIORS (Study of Effects of Nebivolol Intervention on
utcomes and Re-hospitalization in Seniors With Heart
ailure) trial. Of the 2,111 patients included in the SE-
IORS trial, 1,359 (64%) had impaired EF (35%) and
52 (36%) had preserved EF. Over an average 21-month
ollow-up period, nebivolol treatment was associated with
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Highlights From JACC 2009 January 26, 2010:380–407n HR for the primary end point of all-cause mortality or
ardiovascular hospitalizations of 0.86 in patients with
mpaired EF and 0.81 in patients with preserved EF. There
as no significant interaction of EF; the investigators con-
luded that the effects of nebivolol in elderly heart failure
atients was similar in those with impaired and preserved EF.
Beta-blockers are a pharmacologically heterogeneous
roup of drugs, and a study by Rozec et al. (62) helps to
urther differentiate nebivolol, a beta1-selective adrenergic
locker, which also causes nitric oxide-mediated vasodila-
ion, from other drugs in this class. The investigators
valuated the effects of nebivolol on developed peak tension
n endomyocardial biopsy specimens obtained from nonre-
ecting human transplanted hearts. They found that
ebivolol-induced dose-dependent reductions in peak
ension were similar to that seen with a preferential
eta3-adrenergic agonist. The effects of the drug were not
nhibited by nadolol, a beta1,2-adrenergic antagonist, but
ere reduced by use of either a selective beta3-adrenergic
ntagonist or a nitric oxide synthase inhibitor. The
nvestigators concluded that nebivolol activated the
eta3-adrenergic receptor in the human ventricle and that
he nitric oxide-induced negative inotropic effects along
ith previously described coronary microvessel vasodila-
ion could improve myocardial energetics. In an accom-
any editorial, Balligand surmised that over time the
eta3-adrenergic blocking properties of nebivolol along
ith its described antioxidant effects might favorably
ffect cardiac remodeling and that this was a possible
xplanation for the benefits of the drug that were dem-
nstrated in the SENIORS trial (63).
Previous therapies for patients with HFPEF have not
een directed towards underlying pathophysiologic mecha-
isms. Since abnormal collagen metabolism was a feature of
his patient population, Mak et al. (64) performed a ran-
omized controlled trial to assess the effects of selective
ldosterone antagonism on biomarkers of collagen turnover,
nflammation, and Doppler indexes of diastolic function in
atients with HFPEF. They found that procollagen type III
nd I amino-terminal peptides, matrix metalloproteinase
ype-2, interleukin-6 and -8, and tumor necrosis factor-
lpha levels increased in the control group over time.
lthough eplerenone had no significant impact on any of
he biomarkers over the first 6 months, it significantly
ttenuated the increase in procollagen type III amino-
erminal peptide at 12 months. Eplerenone had modest
ffects on Doppler measures of diastolic function. The
esults provide some indication that blocking the effects of
ldosterone may have a role in the management of this
atient population.
Recurrent hospitalizations remain an important and
rowing problem in the management of heart failure pa-
ients. Dunlay et al. (65) provided an interesting community
erspective on this issue by describing the lifetime burden
nd risk factors for hospitalization following heart failure
iagnosis. Studying 1,077 Olmsted County patients diag- iosed with heart failure between 1987 and 2006, they found
3.1% were hospitalized at least once and that 66.9%,
3.6%, and 42.6% were hospitalized2,3, and4 times,
espectively. Of particular note was that noncardiovascular
auses accounted for well over one-half (61.9%) of the
ospitalizations. The investigators reported that male sex,
resence of chronic obstructive pulmonary disease, anemia,
nd a creatinine clearance 30 ml/min were independent
redictors of hospitalization. The investigators concluded
hat the high rate of noncardiovascular causes of hospital-
zation in this population as well as the association with
omorbid conditions could provide a basis for therapeutic
trategies designed to prevent hospitalizations. This study
ocused on outcomes in heart failure patients regardless of
hether the diagnosis was made in the in- or out-patient
etting and emphasizes the importance of comorbidities and
oncardiovascular conditions in determining hospitalization
ates in this population.
In an attempt to explain the heterogeneity in therapeutic
esponse of heart failure patients to beta-blockers, Cresci et
l. (66) performed a prospective longitudinal study examin-
ng the impact on long-term survival of functional polymor-
hisms in the genes encoding beta1-adrenergic receptors
ADRB1), and in G-protein receptor kinase 5 (GRK5), a
ene that regulates beta-adrenergic receptor signaling. The
ohort of 2,460 patients contained 711 African Americans.
atients were genotyped for ADRB1 Arg389Gly and
RK5 Gln41Leu polymorphisms which are more prom-
nent in African Americans. They found that beta-blockers
ncreased survival in Caucasians, but not in African Amer-
cans; African Americans with ADRB1 Gly389Gly GRK5
ln41Gln had a similar survival benefit with beta-blocker
herapy as did Caucasians with the same genotype. From
hese results, the investigators concluded that differences
aused by beta-adrenergic receptor signaling pathway gene
olymorphisms and not race were the major factors contrib-
ting to differences in the effects of beta-blockers between
aucasian and African American heart failure patients.
To better understand the pathophysiology of the cardio-
enal syndrome, Mullens et al. (67) evaluated a cohort of
45 consecutive patients with advanced decompensated
eart failure (ADHF) who had a pulmonary artery catheter
laced to help guide therapy. They found that 40% devel-
ped evidence of worsening renal function (WRF) defined
s an increase of serum creatinine 0.3 mg/dl during
ospitalization. These patients had a greater central venous
ressure (CVP) both before and after treatment than did the
atients who did not develop WRF. Patients in whom CVP
as reduced to 8 mm Hg were significantly less likely to
evelop WRF. CVP was able to stratify risk for WRF across
he spectrum of blood pressure, pulmonary capillary wedge
ressure, cardiac index, and estimated glomerular filtration
ate. The investigators concluded that elevated CVP is the
ost important hemodynamic risk factor for developing
RF in patients with ADHF. The results imply thatncreased attention to lowering CVP should be a goal of the
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January 26, 2010:380–407 Highlights From JACC 2009eart failure hospitalization. In an accompanying editorial,
essup and Costanzo (68) commented that more precise
nformation about CVP and renal function from prospective
rials is needed and that studies designed to assess the effects
f lowering of CVP on renal function and outcomes were
eeded.
Currently available pulsatile devices have limitations in
esign including large pump size, requirement for extensive
urgical dissection for implant, and large body habitus, need
or a large-diameter percutaneous venting lead, audible
ump operation, and a high incidence of reoperation for
evice infection or malfunction. Continuous flow rotary
evices are an alternative that have the potential to be
maller in size and more reliable. Pagani et al. (69) reported
n the outcomes in 281 patients who were urgently listed for
ransplantation who underwent implantation of the Heart-
ate II continuous flow rotary device. After 18 months of
ollow-up, 222 (79%) either underwent transplantation, had
he left ventricular assist device (LVAD) removed after
ecovery, or had ongoing LVAD support. At 6 months,
here were significant improvements in functional class and
-min walk test distance and in quality of life. Major adverse
vents included bleeding, stroke, right heart failure, and
ercutaneous lead infection. Pump thrombosis occurred in 4
atients. The benefits combined with a very low rate of
evice malfunction or infection support the concept that
ontinuous-flow rotary pumps are superior to pulsatile
evices in patients listed for transplantation.
Ypenburg et al. (70) demonstrated that extensive mor-
hological changes occur within 6 months following cardiac
esynchronization therapy (CRT). Reverse remodeling,
easured as the change in LV systolic volume, strongly
redicted hospitalization-free 2-year survival following
RT. These findings enable the clinician to decide which
atients are likely to improve and which are likely to need
dditional interventions such as transplantation following
RT.
lectrophysiology
arcus et al. (71) reviewed the North American ARVC
Arrhythmogenic Right Ventricular Cardiomyopathy) Reg-
stry to assess the efficacy of antiarrhythmic drugs in all
ubjects with an implantable cardioverter-defibrillator
ICD). Ninety-five patients were followed for 480  389
ays. The authors found that beta-blockers were neither
eneficial nor harmful, that sotalol was not effective in
reventing ventricular arrhythmias, and that amiodarone
howed superior efficacy compared with either beta-blockers
r sotalol. Potential limitations of this study include the
mall number of patients receiving amiodarone, and that
revious studies (72,73) showing that sotalol prevented
entricular arrhythmias used electrophysiology testing to
uide therapy. The authors concluded that, since no patients
ied during follow up, use of an ICD was effective therapyn preventing sudden death in these high-risk patients. caissaguerre et al. (74) studied 122 patients with a history
f idiopathic ventricular fibrillation (VF) and early infero-
ateral repolarization on electrocardiogram (ECG); 33 had a
istory of more than 3 recurrent VF episodes and were
ompared with the 89 who did not. Patients with multiple
F had a higher incidence of prior syncope, a higher
ncidence of inducible VF during programmed stimulation,
nd a higher amplitude of J point on baseline ECG.
lectrical storm, seen in 16 patients, was unresponsive to
eta-blockers and calcium-channel blockers, and class 1b,
c, and 3 antiarrhythmic drugs, including amiodarone.
ntravenous isoproterenol suppressed electrical storm
cutely in 100% of patients (n  7) to whom it was
dministered, and oral quinidine prevented recurrence of
F chronically in 100% of patients (n  9) to whom it was
iven over 25  18 months follow-up. The authors con-
luded that early repolarization in the inferior and left
re-cordial ECG leads is a distinct clinical entity associated
ith sudden death (75). In addition, the authors noted that
his syndrome accounted for 31% of aborted, unexplained
udden death in their population. The underlying mecha-
ism of arrhythmia may be related to action potential
eterogeneity across the ventricular wall at the end of phase
depolarization (due in part to differences in Ito current
cross the ventricular wall), which is uniquely responsive to
uinidine. Although this condition has some similarities to
rugada syndrome, it differs in ECG abnormalities, the lack
f sensitivity to sodium channel blockers, and lack of
ssociated conduction defect or SCN5A mutation.
Haqqani et al. (76) performed detailed electroanatomic
apping of the LV endocardium in 17 ischemic cardiomy-
pathy (ICM) patients without clinical sustained mono-
orphic ventricular tachycardia (SMVT) and in 17 ICM
atients with clinical SMVT, in order to identify the
ossible underlying differences in electrophysiologic sub-
trate. They observed no difference in baseline LV diameter,
VEF, infarct territory, or time from infarction, but did
bserve that control patients without clinical SMVT had
maller total low-voltage (1.5 mV) area (30% vs. 55%),
maller very low-voltage (0.5 mV) area (7.3% vs. 29%),
igher mean voltage of low-voltage zones, fewer fraction-
ted, isolated, and very late potentials with lower density of
hese scar-related electrograms per unit low-voltage area,
ess SMVT inducibility, and fewer potential conducting
hannels within dense scar and adjacent to the mitral valve
nnulus. The authors concluded, therefore, that ICM pa-
ients with SMVT had an underlying electrophysiologic
ubstrate that promoted the development of re-entrant
rrhythmias, despite having similar overall ventricular func-
ion compared with ICM patients with SMVT. These
ndings show that inducibility of SMVT in patients with
imilar EF identifies patients at particularly high risk of
udden death, and also suggest that noninvasive means to
dentify the presence of extensive scarring with a high
ensity of areas of slow conduction and myocardial channels
apable of forming re-entry circuits should be further
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Highlights From JACC 2009 January 26, 2010:380–407tudied. These findings also suggest that the current ap-
roach of extensive ablation of myocardial channels between
reas of dense scar or between scar and the mitral valve
nnulus, even in sinus rhythm, may have a valid mechanism
or efficacy.
Myerburg et al. (77) provide an in-depth review of the
ajor randomized ICD trials for primary and secondary
revention of sudden death in patients with ischemic and
onischemic heart disease. By summarizing the results and
imitations of these trials, and their impact on clinical
ractice, this review is helpful to the reader in implementing
hese findings in their clinical practice. The authors also
iscuss in detail the role of ICDs in patients with somewhat
ess common arrhythmogenic disorders, including myocar-
itis, infiltrative diseases, and inherited disorders including
RVC/arrhythmogenic right ventricular dysplasia (ARVD)
nd the channelopathies, despite the relative lack of ran-
omized clinical trials in many of these rare conditions. In
ddition, the authors provide a rather sobering perspective
n the future of how these trials will affect the practice of
udden death prevention, particularly ICD implantation, in
ight of the economic impact that such practice will have.
he authors recommend that further research is required for
etter risk prediction, and particularly, dynamic risk predic-
ion, in order to yield a greater overall benefit of ICD
mplantation in the larger, yet lower risk, populations,
ncluding those at high risk for coronary artery disease, but
o prior event, or the general population. Finally, the
uthors note that by identifying additional funding for such
esearch, a clear limitation identified in earlier studies, and
y creating a formal interaction between the research and
linical enterprises, especially in view of the large impact the
ormer has on the latter, that even modest increments in
unding would potentially have a large economic impact on
linical practice by providing more comprehensive data and
linically useful guidelines.
Dizon et al. (78) reviewed the records of 174 consecutive
eart transplant and 122 double-lung transplant patients in
hom surgery was performed over a period of 3.5 years, for
vidence of atrial fibrillation (AF) as confirmed on ECG by
n electrophysiologist. Clinical variables evaluated from the
erioperative time period and at the time of arrhythmia
ccurrence included biopsy results, immunosuppressive reg-
mens, and echocardiographic measurements. In the heart
ransplant group (A) 4.6% had AF, whereas in the lung
ransplant group (B), 18.9% had AF (p  0.001). The
ncidence of AF in a comparison group of 131 patients with
ormal LV function who underwent CABG was 19.8%.
mmunosuppressive regimens and clinical variables were
imilar for both groups. However, echocardiography re-
ealed no significant cardiac abnormalities in 74% of group
patients compared with 25% of group A patients (p 
.05), and 78% of biopsy results in group B patients were
ormal, whereas only 25% of group A patients had normal
iopsies (p  0.05). Thus, AF is uncommon in heart
ransplant recipients, occurring mainly in the setting of jyocardial dysfunction and graft rejection, whereas AF is
ore common after lung transplantation despite the ab-
ence of graft rejection and cardiac dysfunction. The au-
hors, therefore, conclude that PCI alone cannot explain the
iscrepancy in AF incidence between heart and double-lung
ransplant recipients, but that cardiac autonomic denerva-
ion may have a protective effect for heart transplant patients
n the post-operative setting. The role of parasympathetic
erve (vagal) stimulation has been suggested in other studies
o have a potentially important role in initiation and
aintenance of AF, and that vagal denervation by surgery or
blation may play an important antiarrhythmic role in
revention of AF recurrence.
echanisms of AF. By definition, it has been considered
hat “lone atrial fibrillation” occurs in the absence of cardiac
omorbidities. A study by Stiles et al. (79) challenges this
otion. In 25 patients with paroxysmal lone AF, but
ithout significant AF in the preceding week, and 25
eference patients with left-sided accessory pathways, the
uthors used linear multipolar catheters to study effective
efractory period, conduction time, and conduction charac-
eristics at multiple left and right atrial sites. Compared to
reference” patients, those with lone AF demonstrated
arger atrial volumes, longer refractory periods, longer con-
uction times, slower conduction velocity along the linear
atheters, a greater proportion of fractionated ECGs, ab-
ormal sinus node function, and lower voltage. Thus, these
esults demonstrate a distinct atrial “substrate” even in
atients with paroxysmal lone AF. However, given that
atients with lone AF do enjoy a relatively benign progno-
is, further studies should determine whether their substrate
iffers from, or is simply less marked than, that observed in
F patients with cardiac comorbidities, and define the
elationship between these substrates. These and other
ssues are discussed in the accompanying editorial (80).
A new antiarrhythmic agent for the treatment of atrial
brillation was introduced in the form of dronedarone.
iccini et al. (81) did a comparative efficacy study of
ronedarone and amiodarone for the maintenance of sinus
hythm in patients with AF from all available randomized
ontrol trial data. They compared 4 placebo-controlled trials
f dronedarone with 4 placebo-controlled trials of amioda-
one, and 1 direct comparison between the 2 agents. They
ound that amiodarone was superior to dronedarone (OR:
.49) for the prevention of recurrent AF, but a concomitant
rend toward greater all-cause mortality (OR: 1.6) and
reater overall adverse events requiring drug discontinuation
OR: 1.81) with amiodarone. They estimated that for every
,000 patients treated with dronedarone, there would be
28 more AF recurrences in exchange for 9.6 fewer deaths
nd 62 fewer adverse events with amiodarone. In an
ccompanying editorial, Chan et al. (82) indicate that these
ata remain hypothesis generating, that no definitive con-
lusion can be reached regarding the comparison of these
gents, and that clinicians will have to employ their best
udgment in using these agents.
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January 26, 2010:380–407 Highlights From JACC 2009CD therapy. Several studies in the Journal this year
tudied the impact of psychological factors on outcome in
CD recipients. van den Broek et al. (83) examined the
ombination of anxiety, depression, and distressed or type D
ersonality as predictors for ventricular arrhythmias in
atients with ICDs. In 391 ICD recipients, ventricular
rrhythmias occurred in 19% of patients. Notably, anxious
atients with a type D personality had a significantly
ncreased rate of ventricular arrhythmias (29.6%) compared
ith other ICD patients (16.9%; HR: 1.89). However,
ncreased symptoms of depression or anxiety did not predict
rrhythmias. On multivariate analysis, anxious type D pa-
ients (HR: 1.72) and secondary prevention patients (HR:
.91) were at the greatest risk for ventricular arrhythmias.
hese results suggest that anxious type D patients should be
ffered additional behavioral support after ICD implanta-
ion. In a separate study, Goldstein et al. (84) addressed the
mportant but relatively unstudied issue of whether the topic
f preventing potentially traumatic ICD shocks via ICD
eactivation is discussed in patients near end of life. Inter-
ists and geriatricians were found to be less positive than
lectrophysiologists that their patients understood end-of-
ife choices regarding ICD deactivation. The most likely
arrier to ICD deactivation was a lack of patient awareness
f this possibility. This study reinforces the fact that patient
ducation of device therapy should be comprehensive and
hange over time as an individual’s disease progresses.
There is increasing appreciation and concern for the
otential side effects of ICD therapy. For instance, studies
y Poole et al. (85) from the SCD-HefT (Sudden Cardiac
eath in Heart Failure Trial) database and by Daubert et al.
86) from the MADIT-II (Multicenter Automatic Defibril-
ator Implantation Trial II) database in the Journal in 2008,
uggest that patients who receive ICD shocks have a worse
ubsequent outcome than those who receive no-shock ICD
herapy (i.e., antitachycardia pacing) or no ICD therapy,
ven when shocks are successful. An intriguing report by
ereshchenko et al. (87) showed that ICD therapy may
esult in detectable local injury current in the ICD lead
entricular electrogram, hinting at a potential mechanism
or adverse outcome. Over a mean follow up of 29  15
onths, the authors detected a local injury current (LIC) on
right ventricular (RV) electrogram in 106 of 390 patients,
nd 40 patients suffered heart failure exacerbations. On
ultivariate analysis, patients with LIC were significantly
ore likely to die or to be hospitalized for heart failure (HR:
.69). These results suggest a mechanism to explain the
otential adverse outcome associated with ICD shock ther-
py, and motivate additional strategies to reduce ICD
hocks via ablation (see the following text). These results
ay also help generate hypotheses linking heart failure with
ocal myocardial injury unassociated with elevated serum
ardiac biomarkers.
echanisms of ventricular tachycardia (VT). The mul-
icenter SMASH-VT (Substrate Mapping and Ablation in
inus Rhythm to Halt Ventricular Tachycardia) trial (88) cemonstrated that ablation reduces the incidence of subse-
uent ICD therapy in patients with cardiomyopathy. Cano
t al. (89) performed electroanatomic mapping of the
picardium and endocardium in 22 patients with LV non-
schemic cardiomyopathy and suspected epicardial VT,
ompared to similar mapping in 8 patients with normal
earts and idiopathic VT. The authors found confluent
ow-voltage areas in 18 epicardial (82%) and 12 endocardial
54%) maps, typically at the basal lateral LV. In the 18
atients with epicardial VT, low-voltage area was greater on
he epicardium than endocardium. Ablation targeted to
ndocardial and epicardial low-voltage areas eliminated VT
n 71% of patients at 18 months of follow-up. These results
uide future ablation approaches to patients with nonisch-
mic cardiomyopathy and suspected VT of epicardial origin,
nd also raise mechanistic questions over why the basolateral
V and epicardium are so commonly affected, as discussed
n the accompanying editorial (90).
ong QT syndrome (LQTS). LQTS and its link to
ife-threatening ventricular arrhythmias continues to be an
ctive area of investigation. Clinically, Kirchhof et al. (91)
ystematically studied ECG tracings of patients with ac-
uired and congenital LQTS to provide a clinical index of
remature ventricular complexes that initiated torsades de
ointes, versus those that did not. The authors studied
CG recordings from 35 LQTS patients with torsades de
ointes, from 40 patients with normal QT intervals and
remature ventricular complexes (PVCs), and of PVCs
nrelated to torsades in 24/35 LQTS patients. The authors
ound that abnormal T–U waves (6.2  0.9 mm) directly
receded torsades in 34/35 LQTS patients, and were larger
han T-wave amplitude (2.8  0.2 mm) in control patients
nd larger than the largest T–U-wave in LQTS without
orsades (4.7  0.8 mm). Moreover, the QRS duration of
he first torsades beat (175  12 ms) was longer than in
ontrol PVCs (145 4 ms) and in PVCs in LQTS patients
ot related to torsades de pointes (138 22 ms). These data
ystematically demonstrate that giant T–U waves ominously
ortend the initiation of torsades de pointes in LQTS
atients, and are absent with PVCs that do not initiate
orsades in LQTS patients, or for PVCs in patients with
ther heart disease.
Mechanistically, several studies have examined genetic
ariants that modify the LQTS disease phenotype. Nishio
t al. (92) studied whether D85N, a polymorphism in the
CNE1 gene that encodes the beta-subunit of the cardiac
oltage-gated K channel, is a gene variant that may cause
QTS rather than simply modifying the LQTS phenotype.
he authors performed genetic screening in 317 LQTS
robands, examined D85N in these patients and in 496
ealthy control subjects, and conducted biophysical assays
or the D85N variant in mammalian cells. The authors
ound that allele frequency for D85N carriers was 3.9%
mong LQTS probands compared with 0.81% in healthy
eople. Notably, after excluding 7 of 23 heterozygous
arriers with additional LQTS-related gene mutations, and
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Highlights From JACC 2009 January 26, 2010:380–407female subjects in whom other factors explained their
ymptoms, the prevalence of D85N in LQTS probands
emained significantly higher than in controls. In a heter-
logous expression study with Chinese hamster ovarian
ells, KCNE1-D85N was found to exert significant loss-of-
unction effects on both KCNQ1- and KCNH2-encoded
hannel currents, supporting its mechanistic role in actually
ausing LQTS. Thus, these results support the argument
hat a myriad of genetic “variants” may cause LQTS in
elected patients rather than simply modifying the pheno-
ype of existent LQTS. These and other issues are discussed
n the accompanying editorial (93).
Potentially arrhythmic autonomic modulation of the QT
nterval was studied by Piccirillo et al. (94) in dogs with
acing-induced tachycardia heart failure. The authors com-
ared autonomic nerve activity, measured continuously with
mplanted stellate-ganglion data transmitters in 6 animals,
ith the ECG QT variability index, a previously described
ndex of temporal cardiac repolarization dispersion that
redicts sudden death in heart failure patients (see, for
nstance, Haigney et al. [95]). The authors examined
ntegrated left stellate-ganglion nervous activity, integrated
agus nerve activity for 36 ECG segments recorded at
aseline and 36 after induced congestive heart failure
CHF). Segments were arbitrarily identified as containing
ow or high sympathetic activity. In the high sympathetic
ctivity subgroup, QT intervals and the QT variability index
ncreased from baseline to CHF whereas, in the low
ympathetic activity subgroup, they remained unchanged.
aseline QT variability index correlated inversely with
ntegrated vagus nerve activity, but during heart failure, QT
ariability index correlated directly with integrated left
tellate-ganglion nervous activity. The authors conclude
hat, during heart failure, sympathetic activation is associ-
ted with potentially pro-arrhythmic increases in the QT
nterval and QT variability index. Conversely, under normal
onditions, there was no relationship between sympathetic
ctivation and QT variables. These results shed light on
he mechanisms linking autonomic nervous activity with
udden death in heart failure patients, and also inform the
oninvasive identification of such patients using ECG QT
ndexes.
ther inherited arrhythmic syndromes. Interest in inher-
ted arrhythmic syndromes continues to grow with our
amiliarity with and recognition of affected individuals in
he clinic. A series of papers in the Journal this year focused
n the clinicopathophysiological spectrum encompassed by
linical ARVC. Pieroni et al. (96) studied 30 consecutive
atients with clinical criteria for ARVC via endomyocardial
iopsy at low-voltage ventricular regions identified from
-dimensional electroanatomic mapping. They found ab-
ormal voltage maps (considered to indicate myocardial
eplacement by scar, fibrosis, and/or fat) in 29 patients.
istology and immunohistochemistry of said biopsies con-
rmed the diagnosis of ARVC in 15 patients, and revealed
ctive myocarditis per the Dallas criteria in 15 patients. In a oecondary analyses, the authors suggest that patients with
yocarditis had fewer arrhythmic events on follow-up.
urther studies should determine whether myocarditis in
atients with clinical ARVC is secondary to ARVC, a
athophysiologic process that may occur en route to classical
brofatty replacement, or a distinct entity.
A study by Dalal et al. (97) added important information
o the ongoing debate on the extent of left ventricular
nvolvement in ARVC, and attempted to develop more
pecific diagnostic criteria for the disease. In 38 family
embers of 12 desmosomal mutation-carrying ARVD/
RVC probands, the authors performed genotyping and
ardiac magnetic resonance imaging (CMR). Twenty-five
ndividuals had identified mutations. RV abnormalities were
ssociated with the presence of mutation(s) and with clinical
isease severity. Conversely, LV abnormalities were limited
o intramyocardial fat in 4 individuals, mostly mutation
arriers. CMR confirmed a focal “crinkling” of the RV
utflow tract and subtricuspid regions as previously ob-
erved, dubbed the “accordion sign” by these authors, in
0% of mutation carriers. The prevalence of this sign
ncreased with the clinical severity (by task force criteria).
hus, in these patients in whom LV involvement was
ncommon, the CMR finding of the accordion sign
racked ARVC disease severity. These results may help to
mprove clinical diagnosis of this ARVC, and should be
sed to test whether the presence of these CMR findings
uide prognosis.
The role of sleep-disorder breathing in triggering noctur-
al arrhythmias remains controversial. To study this ques-
ion, Monahan et al. (98) screened the polysomnograms
rom 2,816 patients in the Sleep Heart Health Study for the
resence of paroxysmal AF and nonsustained VT. They
ound that the odds of an arrhythmia occurring after a
espiratory disturbance were nearly 18 times higher than
hat occurring after normal breathing. The absolute rate of
rrhythmia associated with sleep-disorder breathing was
ow. Neither hypoxia nor arousals alone increased arrhyth-
ias. Although infrequent, in a related study, Eleid et al.
99) demonstrated a high prevalence of abnormal nocturnal
ximetry in patients with hypertrophic cardiomyopathy, and
hat patients with abnormal oximetry were more symptom-
tic than their hypertrophic cardiomyopathy colleagues
ithout disordered breathing. In an accompanying editorial,
ilcox and Semsarian (100) indicate that the link between
bstructive sleep apnea and clinical cardiovascular disorders
ncluding AF and hypertrophic cardiomyopathy is rational
ased on the known pathophysiology and may provide a
lue to effective therapy in some patients.
The treatment of ventricular premature beats (VPBs)
ith drugs as a strategy to prevent VF has had a catastrophic
istory as illustrated by the CAST (Cardiac Arrhythmia
uppression Trial). Knecht et al. (101) show promising
ong-term results using ablation of short-coupled VPBs, a
nding that potentially reopens the concept of suppression
f VPBs as a strategy for control of VF. By avoiding the
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January 26, 2010:380–407 Highlights From JACC 2009oxicity of antiarrhythmic therapy, this alternate approach is
romising in selected patients.
chocardiography
side from the standard chest X-ray, echocardiography is
he most mature of all of the imaging modalities. It is well
ntegrated into the daily care of patients with cardiovascular
isease. However, a number of new technologies in appli-
ations continue to evolve.
The prognostic value of exercise echocardiography was
xplored in 4,004 consecutive patients with a normal exer-
ise test (102). In these patients, the change in wall motion
core index was an independent predictor of mortality,
hich yielded incremental value over the clinical, resting
chocardiographic and exercise hemodynamic data. Con-
ersely, an accompanying editorial emphasized that a nor-
al exercise echocardiogram predicted an annual cardiac
eath or infarction rate of only 0.84% and 0.64% (103).
Three-dimensional echocardiography is increasingly used
n clinical practice to evaluate valvular problems (104,105).
n 18 patients with previous mitral annuloplasty or valve
eplacement, ring or valve dehiscence was evaluated with
eal-time 3-dimensional transesophageal echocardiography
106), showing precise definition of the dehisced segment
nd origin of the mitral regurgitation.
The value of diastolic strain changes following exercise as
marker of coronary artery disease was assessed in 162
atients with stable angina (107). The mean strain imaging
iastolic index decreased from 78.0  9.7% to 27.6 
6.0% (p  0.0001) 5 min after exercise in regions perfused
y coronary arteries with stenoses 50% of the luminal
iameter. Possibly, this index provides a very sensitive
arker of coronary artery disease, since diastolic function
bnormalities occur early during the ischemic cascade (108).
ssessment of cardiac deformation. Myocardial defama-
ion, usually based upon measurements of strain, can depict
yocardial performance independent of variables of overall
ardiac motion and tethering to adjacent myocardium in-
erent in endocardial motion. Utilizing tissue Doppler and
peckle tracking methodologies, echocardiography can de-
ineate strain and myocardial rotation as well as ventricular
orsion. Ishii et al. (109) applied speckle tracking techniques
o transverse strain to study the prevalence and duration of
iastolic dysfunction following myocardial ischemia induced
n the setting of angioplasty. They observed that strain
ecame abnormal during both systole and the first one-third
f diastole during coronary occlusion in the affected seg-
ents, but that only diastolic strain remained abnormal
ollowing reperfusion. Diastolic strain was decreased for
4 h, establishing the potential for persistent diastolic
ysfunction (stunning) to detect post-ischemic memory.
Cho et al. (110) compared global 2-dimensional strain to
tandard ventricular EF to predict clinical events in 201
eart failure patients followed for 39  17 months. In
ultivariate analysis, age and the global circumferential ttrain were independently associated with cardiac events,
emonstrating that global circumferential strain is a more
otent prognosticator of cardiac events than EF in heart
ailure patients. In an accompanying editorial, Lafitte (111)
ointed out that measurement of circumferential strain may
e limited in quality and reproducibility, and that a multi-
riteria echocardiographic analysis of LV function remains
ttractive in assessing patients with heart disease. In another
tudy, Tann et al. (112) applied ultrasound measures of
efamation to study the pathophysiology of heart failure
ith normal EF (diastolic failure) at rest and during
xercise. As compared with controls, they observed that
ystolic longitudinal and radial strain, mitral annular veloc-
ties, and apical rotation were lower in the diastolic failure
atients at rest and failed to increase normally with exercise.
hey concluded that widespread abnormalities of both
ystolic and diastolic defamation are present in the setting of
eart failure with normal EF and are exposed with exercise.
n an accompanying editorial, Marwick (113) pointed out
hat this study demonstrated that the abnormalities of
elocity, rotation, and defamation resulted in an abnormal
wisting of the apex with delayed untwisting resulting in
educed suction in increased end-diastolic pressure on ex-
rcise. These data were attractive in providing a unifying
oncept of systolic and diastolic abnormalities accounting
or heart failure in the setting of a normal EF.
ontrast echocardiography. Although nitric oxide is a gas
ith substantial beneficial potential, it is extremely difficult
o deliver systemically. Therefore, Huang et al. (114)
eveloped a methodology to administer nitric oxide utilizing
chogenic liposomes as a gas carrier. They observed that
ncapsulation of nitric oxide with argon reduced intimal
yperplasia by 40% in a rabbit model of carotid atheroscle-
osis. This study represents another step forward in the
pplication of contrast microbubble agents to deliver ther-
peutic agents.
Although time–intensity curves produced by contrast
chocardiography have been primarily used to study myo-
ardial perfusion, Womack et al. (115) applied this tech-
ique to assess skeletal muscle capillary perfusion in patients
ith diabetes with and without microvascular complica-
ions. They obtained time–intensity curves from the forearm
exor muscles at rest and during high-intensity handgrip
xertion. They observed an approximately 50% reduction in
apillary recruitment at rest and 60% to 70% reduction with
xertion in patients with diabetes and microvascular com-
lications, patients who also demonstrated greater insulin
esistance and whole blood viscosity. This study demon-
trated a useful clinical application of contrast ultrasound to
tudy peripheral vascular abnormalities. In an accompanying
ditorial, Porter (116) observed that these data demonstrate
hat it will be important to evaluate pathological vascular
esponses in the microcirculation as well as in larger vessels
n diabetic patients, and contrast echocardiography is par-
icularly well suited to this task.
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Highlights From JACC 2009 January 26, 2010:380–407ole of echo in resynchronization. A pressing need exists
o identify those patients who fulfill current indications for
ardiac resynchronization who will benefit from biventricu-
ar pacing, and echocardiography has been the technique
ost prominently considered for this purpose. However, as
eviewed by Bax and Gorcsan (117), the PROSPECT
Predictors of Response to Cardiac Resynchronization
herapy) study failed to demonstrate that echocardiography
ould reliably predict those patients who would benefit from
esynchronization therapy. The authors reviewed the mul-
iple variables that may have influenced the results of the
ROSPECT study, including patient selection, technical
ssues involved in performing the studies, and the presence
f myocardial scar, and the ability to pace the most
yssynchronous area of myocardium. In this same issue,
awkins et al. (118) contributed a Viewpoint that argued
hat cardiac dyssynchrony identified by echo did not have a
ignificant role in selecting patients to undergo cardiac
esynchronization. However, in an accompanying commen-
ary, Sanderson (119) argued that it was critically important
o be able to identify those patients who should receive
iventricular pacing, that echocardiography had shown
romise in this regard, and that future studies should be
irected to improving the technique so that it is more
ccurate. These 3 papers present well the current state of
nowledge and controversy regarding the role of echo in
esynchronization therapy, and seem to reach a consensus
hat more work is needed before echo can reliably serve in
his capacity.
ntracardiac echocardiography (ICE). The use of intra-
ardiac imaging to guide noncoronary interventions is re-
eiving increasing attention. This area was reviewed by Kim
t al. (120) who pointed out that ICE has been the primary
odality used for this purpose. Thus far, ICE has been used
o guide transseptal heart catheterization, to guide catheter
blation of cardiac arrhythmias, and to assist in the percu-
aneous closure of atrial septal defects and patent foramen
vale as well as in the performance of mitral valvuloplasty. It
ould appear that ICE has achieved acceptance as a
aluable tool for the performance of a variety of noncoronary
ardiac interventions. (120).
T and Nuclear Imaging
arious studies addressed the expanding role of cardiac CT
maging. Budoff et al. (121) used the MESA (Multi-Ethnic
tudy of Atherosclerosis) study to assess the predictive value
f calcium scores for future events in 6,814 subjects over 3.8
ears. They found calcium scores to be highly predictive of
ncident coronary disease, and that absolute scores were
ore predictive than age–sex percentile scores. Moreover, as
mphasized in an accompanying editorial, these calcium
cores retained their discriminative power independent of
he presence/absence of traditional risk factors (122). Doc-
mentation of an elevated coronary calcium score signifi-
antly increased the chance of additional cardiac testing puring follow-up in an analysis of 1,361 subjects by Shaw et
l. (123). By 1 year of follow-up, 9.4% of subjects with a
alcium score of 0 to 10 had 1 or more additional nonin-
asive tests. By contrast, among patients with calcium scores
f 1,000 or more, 58.1% had further noninvasive testing,
nd 12.0% had coronary revascularization. Still, the pres-
nce and extent of coronary artery calcium do not necessarily
ndicate or exclude myocardial ischemia. Chang et al. (124)
valuated 1,126 asymptomatic subjects who had coronary
rtery calcium scoring with electron beam CT and nuclear
erfusion imaging (single-photon emission computed to-
ography [SPECT]) followed for a median of 6.9 years. An
bnormal SPECT result increased in parallel to an increas-
ng calcium score from 1% in patients with a score 10 to
9% in patients with a score 400 (p  0.001). Moreover,
n patients with a normal SPECT, coronary calcium score
rovided incremental prognostic information with a 3.55-
old increase for any cardiac event when the score was400
s compared with 10.
Prospective gating CT angiography can decrease radia-
ion dose without reducing diagnostic accuracy for detecting
tenoses (125). Assessment of myocardial perfusion by CT
ngiography enables relation of anatomic stenoses to hemo-
ynamic. A direct comparison between SPECT and stress-
est CT perfusion imaging (average dose of 12.7 mSv) was
erformed in 33 patients (126). The diagnostic accuracy of
T was comparable to SPECT for detection of significant
oronary artery stenoses.
In patients with coronary stents, CT imaging could
efine stent gaps not easily detected on invasive angiography
127), which were associated with 28% in-stent restenosis
28%). Cardiac CT can also be applied in patients receiving
ercutaneous aortic valve replacement, for precise assess-
ent of prosthesis deployment (128).
Various advances in nuclear imaging were reported.
mong 1,056 consecutive patients who underwent physio-
ogical exercise SPECT perfusion imaging, 473 achieved
10 metabolic equivalents without ischemic ST-segment
hanges during exercise; none of these had significant
schemia on SPECT (129). In these patients, it may be
onsidered to eliminate SPECT imaging and thus save
ubstantial costs (130).
Approximately 50% of SPECT myocardial perfusion
tudies are performed with vasodilator stress. Regadenoson
s a selective A2A agonist (131) which can be given as an
ntravenous bolus at a fixed dose, with fewer side effects,
ncluding atrioventricular block and bronchospasm, and
ay thus further optimize pharmacological SPECT perfu-
ion imaging. Nuclear imaging using iodine-123 metaiodo-
enzylguanidine provides information on cardiac adrenergic
erve activity, and abnormalities have been associated with
oor outcome in heart failure patients. In 106 patients with
ild-to-moderate heart failure, it was shown that abnormal
racer washout rate was predictive of sudden death, inde-
endently of LVEF (132). In these patients, signal-averaged
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redictive.
Positron emission tomography (PET) with N-13 ammo-
ia was applied in 229 patients for absolute quantification of
yocardial perfusion and coronary flow reserve (133). Pa-
ients with abnormal perfusion had worse outcome over a
ollow-up period of 5.4 years; in patients with normal
erfusion, abnormal coronary flow reserve (2.0) was asso-
iated with a significantly higher event rate and cardiac
eath rate. Addition of coronary flow reserve to perfusion
ay further improve risk stratification with PET (134).
ince PET permits absolute blood flow quantification, this
echnique is ideal for detecting subtle abnormalities in
atients with metabolic syndrome and diabetes, even in the
bsence of overt coronary artery disease (135). In addition to
erfusion imaging, cardiac metabolism and innervation can
lso be quantified with PET. Furthermore, with the intro-
uction of hybrid PET-CT systems, the integration of
natomic and physiologic imaging will become more pop-
lar over the next years (136). This concept was applied in
n animal model of intramyocardial stem cell therapy, in
hich PET-CT was used to register and track the stem cells
labeled with the PET tracer F-18 fluorodeoxyglucose) (137).
hese molecular imaging techniques may aid in better under-
tanding of the fate of stem cells after injection (138).
CT coronary angiography provides a noninvasive
ethod to rule out obstructive coronary disease, but there
re relatively few data on patient outcomes. Hoffman et
l. (54) performed CT angiograms in 368 consecutive
ow-risk chest pain patients evaluated in the emergency
epartment, without use of the results in clinical care.
ne-half of the patients were free of coronary disease and
ithout coronary event, indicating that a negative CT
ngiogram has high negative predictive power in low-risk
atients with acute chest pain.
Cardiac CT angiography studies also turn up incidental
ndings in the lungs and mediastinum, the significance of
hich is controversial. MacHaalany et al. (139) found 1 or
ore noncardiac incidental findings in 42% of 966 patients.
nly 1% of patients had findings of immediate clinical
ignificance, and a further 7% had findings that required
ollow-up. Over the subsequent 18 months, the cost of
ollow-up studies averaged $1,038 per patient, and an
verage of 1.1 additional CT scans. It is difficult to judge
hether the cost and additional radiation exposure was
ustified by the small yield of clinically important findings.
Suaya et al. (140) used propensity score matching and
nstrumental variables methods to assess the effect of cardiac
ehabilitation on mortality. Their results suggest a signifi-
ant reduction of mortality due to rehabilitation, ranging
rom 21% to 34%, depending on the methods used. The
tudy is important in applying several alternative methods of
nalysis to the same dataset, and helps to improve the
ethods of observational analysis.
The relationship between volume of PCI procedures andlinical outcomes has been very controversial, in part be- gause many interventionalists perform relatively low vol-
mes. Srinivas et al. (141) examined the relationship be-
ween volume of primary PCI procedures and the outcome
f patients with AMI using data from the New York State
egistry. They found that the effect of physician volume on
utcome was modified by the hospital volume, with the
oorest outcomes found with low-volume operators in
ow-volume hospitals.
Readmissions of Medicare patients has drawn increased
crutiny of policymakers, who believe reducing such admis-
ions would simultaneously decrease costs and increase
uality of care. Readmissions within 30 days of a PCI
rocedure were found to be quite common: 15% in an
nalysis of a cohort of some 315,000 Medicare patients by
urtis et al. (142). A repeat revascularization procedure was
erformed in only 28% of these readmissions, although
ost of the readmissions were for cardiac indications.
learly, more study of this issue is needed to clarify whether
he readmissions reflected lower quality of care, a poor
ransition between inpatient and outpatient care, or simply
he underlying severity of illness in these patients.
Second-hand smoke is associated with increased risk of
ardiovascular disease, which is one of the major reasons for
anning smoking in public places. Meyers et al. (143)
nalyzed 10 studies of the effects of smoking bans, report
hat there was a 17% lower risk of AMI in localities that
anned public smoking compared with localities that did
ot. This study, along with a recent Institute of Medicine
eport, should accelerate passage of local ordinances ban-
ing public smoking.
The importance of intensive glycemic control among
atients with diabetes has been controversial, with random-
zed studies suggesting that macrovascular outcomes may
ot be improved. Aguilar et al. (144) reported a provocative
nding of a “U-shaped” relationship between hemoglobin
1C levels and outcomes among patients with heart failure
nd diabetes. This finding adds further fuel to the fire about
he optimal approach to management of patients who have
oth diabetes and heart disease.
RI
n the field of MRI, considered by most imagers as the
ltimate cardiovascular phenotyping modality, JACC pub-
ished the most important breakthroughs regarding transla-
ional and clinical applications of cardiac MRI. The most
mportant development in the field was the maturity and
linical translation of techniques based on T2 imaging to
etect myocardial edema and thus characterize the total
olume of myocardium at risk during coronary occlusion.
he translation of these techniques to clinical cardiology has
een pioneered in North America by groups working at
niversity of Calgary (M.G. Friedrich and collaborators)
nd at the National Heart, Lung, and Blood Institute (A.
rai, A. Aletras, and collaborators). This year, the Calgaryroup published fundamental subclinical studies in JACC
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Highlights From JACC 2009 January 26, 2010:380–407145) that establish the pathophysiologic time course of
yocardial edema formation and its potential use as the
arlier imaging markers of myocardial injury following
oronary occlusion and ischemia. The paper is accompanied
y a comprehensive editorial reviewing the state of the art of
2 imaging in cardiovascular research and medicine (146).
Upstream from myocyte injury in the ischemic causation
hain, magnetic resonance has been used to probe micro-
ascular function as well as larger arterial obstruction and
emodeling. Novel methods begin to find their way as
romising cardiovascular applications as demonstrated in
he articles by Wu et al. (147) and Anderson et al. (148).
oth techniques follow the usual trail of cardiovascular
agnetic resonance methods development which com-
only begin deployment in vascular beds and target organs
ther than the coronary arteries and the heart. In the first
tudy, continuous arterial spin-labeling perfusion MRI was
sed to study microvascular flow impairment associated
ith different degrees of peripheral artery disease (PAD). In
he second, the elegant combination of arteriography, per-
usion, and spectroscopy was used to demonstrate that there
xists a dissociation between cellular metabolism and tissue
erfusion in peripheral vascular disease. The accompanying
ditorial by Dewey (149) puts in perspective the findings
rom the latter report in the evaluation of patients with
eripheral vascular disease. In terms of vascular imaging,
R angiography inches its way to study the coronaries in a
linically meaningful manner as 3.0-T systems become
vailable primarily for neurologic applications. In the last
ear, JACC published an important paper by Yang et al.
150) showing the benefits of harnessing the extra signal-
o-noise margin created by MR 3.0-T imaging to enhance
he power to evaluate the coronary arteries. The accompa-
ying editorial by Sibley and Bluemke (151) briefly reviews
he “state of the art” of coronary imaging by MRI and
ighlights its potential application to investigate coronary
emodeling in population studies such as the MESA (152).
This year, the clinical value of MRI in patients with heart
ailure has become well established. As the gold-standard
ethod to assess cardiac morphology and tissue character-
stics, the value of MRI in heart failure was illustrated by
arious efforts at characterizing hypertrophic cardiomyopa-
hy (153), the beneficial effects of pronounced weight
eduction by bariatric surgery and diet (154) as well as
ardiac energetics in heart failure with preserved systolic
unction, probed by MR spectroscopy (155). The role of
RI in heart failure was comprehensively reviewed by the
xford group (156), including the clinical methods of tissue
haracterization by contrast enhancement in the study of
ilated, hypertrophic, and restrictive cardiovascular disease.
n this regard, the risk of nephrogenic systemic fibrosis
econdary to gadolinium contrast utilization in patients with
enal impairment was also reviewed by Kribben et al. (157),
iven the increasing importance of contrast enhanced MRI
ethods to the cardiologist’s current clinical practice. Fi-ally, safe utilization of MRI in patients with pacemakers mnd defibrillators continues to expand and JACC ’s leader-
hip in this important technologic development was high-
ighted by the publication of an original study testing the
fficacy of precautions devised to assure safety and quality of
RI studies in patients with cardiac devices (158), dis-
ussed in detail by an accompanying editorial by Roguin
159), one of the pioneers in this field. Indeed, 2009 was a
right year for MR investigators, patients, and cardiologists,
s documented by the reports, editorial comments, and
eviews published on this topic by JACC.
Although maturing quickly, the clinical role of CMR in
aily practice remains uncertain. To answer this question,
ruder et al. (160) analyzed the results of a very large
ulticenter EuroCMR (European Registry) involving
1,040 consecutive patients. They reported the indications
or performing this study and the complication rates that
ere involved. Of significance, they indicated that clinical
anagement was impacted in two-thirds of patients; and in
6% of the cases, the final diagnosis based on CMR was
ifferent from that prior to study. These data provide strong
vidence for the fact, that at least in these European centers,
MR has achieved an important role in the daily clinical
ractice of cardiology.
CMR is achieving an increasing role in the clinical
nvestigation. In this regard, Tang et al. (161) employed
MR imaging using ultrasmall superparamagnetic iron
xide (USPIO)-enhanced carotid MRI to compare the
ffects of 10 versus 80 mg of atorvastatin on carotid plaque
nflammation. Forty-seven patients with carotid stenosis of
reater than 40% who demonstrated intraplaque accumula-
ion of USPIO on MRI were randomized to either 10 or 80
g of atorvastatin for 12 weeks. The 80-mg atorvastatin
roup manifested a significant reduction from baseline in
nflammation by USPIO at 6 and at 12 weeks. Thus, these
ata demonstrate that MRI can be used to assess the
harmacologic efficacy of treatment with regard to patho-
hysiological phenomena such as inflammation. In an ac-
ompanying editorial, Fayad et al. (162) point out that there
re many technical considerations to obtaining high-quality
SPIO images, and that lymphatic uptake may interfere
ith interpretation. However, these editorialist agree that
he existing data provide a stimulus for further investigation
n this area.
alvular Heart Disease
novel concept to evaluate aortic stenosis severity is the
alvuloarterial impedance; the prognostic value of this index
as assessed in 544 asymptomatic patients with moderate-
o-severe aortic stenosis (107). Patients with an index 4.5
m Hg·ml1·m2 had a 2.76-fold increased mortality risk
fter adjustment for other risk factors and treatment (sur-
ery or medical). This new index may potentially further aid
n risk stratification of asymptomatic patients withoderate-to-severe aortic stenosis (163).
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January 26, 2010:380–407 Highlights From JACC 2009Hemodynamic performance of percutaneous and surgical
ortic valve bioprostheses was compared in 150 patients who
nderwent surgical or percutaneous valve replacement for
evere aortic stenosis (164). Echocardiography demon-
trated a significantly lower transprosthetic gradient in the
atients with percutaneous valve replacement as compared
ith the surgical patients. Conversely, post-procedural aor-
ic regurgitation was encountered more often in the patients
ith percutaneous valve replacement. Long-term outcome
ata are needed to further compare surgery with percutane-
us valve replacement.
The entity of low-gradient severe aortic stenosis in the
etting of normal LV function due to reduced LV stroke
olume has recently drawn considerable attention. Believing
hat valvuloarterial impedance may play a role in this
rocess, Hachicha et al. (108) determined to study the
rognostic value of valvuloarterial impedance in asymptom-
tic aortic stenosis since it is a superior index of global
emodynamic load faced by the LV. They retrospectively
nalyzed the data in 554 consecutive patients having at least
oderate aortic stenosis without symptoms. The 4-year
urvival was significantly lower in patients with a baseline
alvuloarterial impedance greater than and equal to 4.5, and
ortality was increased by 2.76-fold in such patients. Thus,
ncreased valvuloarterial impedance clearly represents an
xcessive LV hemodynamic load and can be used to predict
atients who are asymptomatic with significant stenosis in
hom a poor outcome is likely.
The management of patients with low-flow/low-gradient
ortic stenosis without contractile reserve continues to be
roblematic. Tribouilloy et al. (165) retrospectively analyzed
he data in 81 such patients who were either referred for
urgery or treated medically. In 42 propensity-matched
atients, 5-year survival was markedly by aortic valve re-
lacement (65% vs. 11%, p  0.01). Associated bypass
urgery and a maximal gradient of less than 20 mm Hg were
ndependently predictive of operative mortality. Thus, these
ata would suggest that, despite a formidable operative
ortality, patients with low-flow/low-gradient aortic steno-
is are best served with surgery if at all possible.
An alternative to operative aortic valve replacement is
ercutaneous aortic valve replacement. In a state-of-the-art
aper, Zajarias and Cribier (27) reviewed the state of
ercutaneous aortic valve replacement. They point out that
t is a field in rapid transition, but that the Edwards
APIEN and CoreValve devices are being used and evalu-
ted in many patients throughout the world. They indicate
hat mid-term follow-up studies are very encouraging with
egard to the absence of restenosis or prosthetic dysfunction.
The role of the endothelium of the aortic valve cusps
hemselves in the genesis of aortic valve disease is just now
eceiving attention. In a novel study, El-Hamamsy et al.
166) studied the mechanical properties of porcine aortic
alve leaflets subjected to compounds capable of altering
eaflet stiffness. They observed that serotonin induced a
ecrease in leaflet stiffness which was reversed by L-NAME rr endothelial denudation, whereas endothelin-1 caused an
ncrease in stiffness. These data clearly established the ability
f the endothelium to regulate the mechanical properties of
ortic valve leaflets, and point to a possible role in the
enesis of aortic valve disease. In an accompanying editorial,
immons (167) points out that valve mechanics have largely
een viewed as an engineering issue in the past, but that
here is an increasing appreciation for valve biology which
ay play an important role both in physiology and disease.
he percutaneous treatment of mitral valve disease is also
eing pursued. Feldman et al. (168) reported the most
ecent findings in the EVEREST (Endovascular Valve
dge-to-Edge REpair Study) in which mitral valve repair is
chieved with a mitral valve clip system. They reported on
07 patients followed for at least 12 months and indicated
hat 66% of the 76 successfully treated patients were free
rom death, mitral valve surgery, or mitral regurgitation of
2 severity. These results early in the learning curve of
he use of this device are considered encouraging, and
urther studies are continuing.
re-Clinical Research
denosine may decrease infarct size after ischemia-
eperfusion, but its utility as a cardioprotective agent is
imited by a short half-life and systemic side effects of
ypotension and bradycardia. Takahama et al. (169) postu-
ated that liposomes, which have been used in chemother-
py, may be used to deliver adenosine to ischemic myocar-
ium, where vascular permeability is increased due to
ndothelial damage. Encapsulating liposomes with polyeth-
lene glycol (PEG) can prolong the residence time and
elay the degradation of adenosine. A 10-min intravenous
nfusion of PEGylated liposomal adenosine to rats with
AD occlusion, started 5 min prior to reperfusion, resulted
n liposome accumulation in the border and infarct zones
ithout hypotension or slower heart rates. There was a
ose-dependent decrease in infarct size at 3 and 72 h, which
id not occur with empty PEGylated lyosomes or free
denosine. The cardioprotective effects PEGylated liposo-
al adenosine were blocked by nonspecific and specific
denosine receptor antagonists. Cohen and Downey (154)
n an editorial comment note that exogenous adenosine has
een used to salvage ischemic myocardium in both preclin-
cal and clinical studies with mixed success. The limitations
f adenosine could be overcome by using PEGylated lipo-
omes for drug delivery and targeting vehicle, which can be
onveniently administered by an intravenous route without
ignificant toxicity. This and other studies confirm that
ardioprotective effects are inhibited by adenosine receptor
ntagonists.
ovel cardioprotective compounds in pre-clinical
schemia-reperfusion. Glucagon-like peptide (GLP)-1 is
gut incretin hormone with insulinotropic and insulinomi-
etic properties that is cardioprotective in ischemia-eperfusion, but has a short half-life that requires continu-
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Highlights From JACC 2009 January 26, 2010:380–407us infusion. Timmers et al. (170) postulated that exenatide, a
ong-lasting GLP-1 analog, may be a useful alternative. This
nteresting compound derived from the saliva of venomous
izard gila monster, is a Food and Drug Administration–
pproved drug (Byetta from Amylin and Lilly) used to treat
ype 2 diabetes mellitus. In pigs with 75 min of left
ircumflex coronary artery occlusion, exenatide given prior
o reperfusion and then injected subcutaneously twice daily
ecreased infarct size by 40% after 3 days. Exenatide
ncreased insulin levels without inducing hypoglycemia,
ctivated protective pAkt signaling, decreased apoptosis and
xidative stress, and improved systolic and diastolic LV
unction. Webb et al. (171) in an editorial comment note
his is a highly translational study in a clinically applicable
arge animal model that adds support to the use of incretin
nalogs, since GLP-1 has been cardioprotective in preclin-
cal and clinical studies. It is unclear whether the mecha-
isms of cardioprotection are related to exenatide and/or
ncrease in insulin, or if the decrease in apoptosis and
xidative stress contribute to the beneficial effects.
ovel targets for attenuating LV remodeling after MI:
re-clinical study. Buss et al. (172) tested the hypothesis
hat adverse LV remodeling after MI may be inhibited by
argeting the mammalian target of rapamycin (mTOR)
athway. This pathway is involved in ventricular hypertro-
hy and remodeling and is clinically relevant, as mTOR
nhibitors are used for immunosuppression in transplant
atients and to prevent proliferation in drug-eluting stents.
verolimus, an inhibitor of mTOR, was given orally to rats
or 3 days after ligation of the LAD. Early treatment
ecreased infarct size, improved LV function and reduced
emodeling 28 days after the MI. This was associated with
ncreased autophagy (mTOR is a major regulator of this
nique form of cell death), decreased NF-kappa B activity
n the border zone, decreased macrophage invasion, and
nflammation. The improvement in LV function was sus-
ained for 3 months, even when everolimus was stopped
fter the first month. Delayed everolimus treatment initi-
ted 3 days after MI did not alter infarct size, but still
ignificantly improved LV remodeling and LV function.
hese results demonstrate the feasibility of targeting
TOR to improve LV remodeling with a clinically available
TOR inhibitor.
ovel methods to improve LV remodeling after MI:
re-clinical study. Biomaterials injected into the heart
ave restraining effects that limit LV remodeling after MI.
eor et al. (173) tested the feasibility and safety of intra-
oronary injection of a calcium cross-linked alginate solu-
ion 4 days after anterior wall infarction in pigs. This
ompound is nonthrombogenic and forms a hydrogel scaf-
old in the infarcted region, which gradually dissolves and is
eplaced by myofibroblasts and collagen after 60 days.
njecting the alginate hydrogel did not cause significant
rrhythmias, increase in troponin, inflammation, or fibrosis.
here was a dose-dependent decrease in the extent of LV
ilation, improved LV function, and 50% increase in scar ohickness. The feasibility, safety, and effectiveness of this
iomaterial to improve LV remodeling in a large animal
odel moves this novel approach a step closer towards
linical translation.
he role of monocytes in patients with AMI. Monocytes
lay an important role in ischemic heart disease, but do
ot represent a homogeneous population of cells. Tsu-
ioka et al. (174) used flow cytometry to identify 2 distinct
ubsets of circulating monocytes based on the expression
f CD14 and CD16 in 36 patients undergoing primary
CI for STEMI. Circulating monocytes identified as
D14CD16 increased with a peak at 3 days, whereas
D14CD16 monocytes peaked 5 days after MI. Peak
evels of CD14CD16, but not of CD14CD16
onocytes were negatively associated with the extent of
yocardial salvage 7 days after MI, as assessed by CMR,
nd were inversely associated with the extent of recovery in
V function (change in EF) 6 months following MI.
anipulating monocyte subsets that affect myocardial sal-
age may be a novel therapeutic target for patients with
MI.
Shantsila and Lip (175) make editorial comments on the
iversity of monocytes and their functional role.
D14CD16 monocytes produce inflammatory cyto-
ines, reactive oxygen species and proteolytic enzymes and
lay an important phagocytic role to digest necrotic tissue in
I. This may be related to increased expression of mono-
yte chemoattractive protein (MCP)-1, which attracts
onocytes and contributes to angiogenesis in the early
hase of an AMI. In contrast, CD14CD16 monocytes
re mobilized with exercise and correlate with atherogenic
ipids, but were not associated with outcomes and have an
nclear role in AMI.
The role of monocytes generated significant interest from
avsak and Jaffe (176), who did not find a temporal increase
n MCP-1 within 12 h in 216 patients with ACS. Shantsila
nd Lip (177) reply the time in their study (3 to 12 h) may
e too early to observe an increase in monocytes that peaks
fter 48 to 72 h, and other large clinical ACS studies have
ound an increase in MCP-1 with prognostic significance.
manashi et al. (178) concur it will be important to study
ore diverse groups, including patients with non-STEMI,
o determine whether measuring monocyte subsets help to
valuate the optimal timing for interventions in ACS.
lycemic control in patients with AMI. The role of
yperglycemia was examined in 88 patients with a first AMI
dmitted for surgical coronary revascularization (179). Pa-
ients with hyperglycemia (glucose 140 mg/dl) were ran-
omized to receive insulin to achieve intensive (lower
lucose to 80 to 140 mg/dl), or conventional (maintain
lucose at 180 to 200 mg/dl) glycemic control for 3 days
rior to surgery. Patients with hyperglycemia had worse
V function than the 38 patients with normoglycemia
glucose 140 mg/dl), but it was better in patients with
ntensive than with conventional glycemic control. Biopsies
f the peri-infarct area showed greater nitrotyrosine, iNOS,
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January 26, 2010:380–407 Highlights From JACC 20092-production, macrophages, T-lymphocytes, TNF-alpha,
nd caspase-3 levels in hyperglycemic patients, which was
ttenuated with intensive compared with conventional gly-
emic control. Thus, tight glycemic control reduces oxida-
ive stress, inflammation, apoptosis, and improves LV func-
ion in AMI. Dandona et al. (180) in an editorial comment
ote these results are important in the context of several
arge clinical trials evaluating glucose and insulin in AMI.
lthough glucose-insulin-potassium solutions failed to im-
rove outcomes in a large prospective randomized trial
CREATE–ECLA [Clinical Trial of Reviparin and meta-
olic Modulation in Acute Myocardial Infarction Treat-
ent Evaluation–Estudios Clinicos Latino America]), that
rial demonstrated an adverse effect of hyperglycemia on
ortality. Several studies have shown that insulin has
nti-inflammatory and profibrinolytic independently of its
ffects on glucose, which may be cardioprotective. The
resent study by Marfella et al. (179) shows the beneficial
ffects of insulin on cardiac function with AMI that corre-
ate with histological changes in inflammation and apoptosis
n the human myocardium.
argeting the cardiac ryanodine receptor to decrease
iastolic calcium leak in experimental heart failure. Cal-
ium may leak from the sarcoplasmic reticulum (SR) with
bnormalities in the skeletal muscle ryanodine receptor
RyR1) to cause malignant hyperthermia, and in cardiac
yanodine receptors (RyR2) to predispose to malignant
rrhythmias. On the basis of similar positions of mutations
n RyR1 and RyR2, Kobayashi et al. (181) found that
antrolene, a drug that binds to RyR1 to treat malignant
yperthermia, also binds and stabilizes cardiac RyR2. Dan-
rolene corrected defects in interdomain interactions of
yR2 in isolated cardiomyocytes from dogs with pacing-
nduced heart failure to decrease diastolic SR calcium leaks,
ecrease delayed afterdepolarizations, and improve cell
hortening and calcium transients. Stabilization of RyR2
ith dantrolene is a novel approach to treat heart failure.
hannon and Lew (182) in an editorial comment note
everal interrelated mechanisms may contribute to abnormal
R calcium leak, including increased phosphorylation of
yR2, enhanced sensitivity to luminal SR calcium, and
eakened interdomain interactions of RyR2. The current
tudy demonstrated that this last mechanism occurs in heart
ailure, and can be treated with dantrolene to decrease SR
alcium leak. It is unknown if the benefits are limited to
utations at dantrolene binding sites, which cause arrhyth-
ias and sudden death in some cases of catecholaminergic
olymorphic VT and atypical RV cardiomyopathy. If dan-
rolene has broader effects to decrease SR calcium leak, it
ay be a useful adjunct to treat heart failure. Dantrolene has
een used for decades to treat acute malignant hypothermia
nd chronic muscle spasticity after spinal cord injuries and
trokes, but may be require higher doses to stabilize RyR2 in
eart disease. Hlpha-1-adrenergic receptor (AR) subtypes in human
oronary arteries. Jensen et al. (183) examined the distri-
ution and subtypes of alpha-1- and -2-ARs in human
picardial coronary arteries from 19 transplant recipients
nd 6 unused donors. There are scant data on the distribu-
ion and function of alpha-1-AR and -2-AR in humans,
hich play important regulatory roles in coronary vasomo-
or tone and blood flow. The alpha-1-AR mediate constric-
ion of large epicardial coronary arteries and arterioles,
hereas alpha-2-AR act on the coronary microcirculation.
f the 3 molecular subtypes of alpha-1-AR, messenger
ibonucleic acid (mRNA) expression and protein were the
ost abundant for the alpha-1D subtype in the coronary
rteries, whereas alpha-1A and -1B subtypes played only a
inor role. There was alpha-1D–induced activation of
xtracellular signal-regulated kinase in coronary smooth
uscle cells with low levels of norepinephrine, indicating
he function significance of these receptors. This is consis-
ent with the high affinity of alpha-1D-AR for norepineph-
ine, which causes constriction at low doses. These results
ave clinical implications with the widespread use of non-
elective alpha-AR inhibitors (e.g., to treat prostate hyper-
rophy) and emergence of selective alpha-AR antagonists.
Braun and Insel (184) note the importance of human data
n an editorial comment aptly titled “The Best ‘Model
ystem’ for Human (Coronary Arteries) Is Human.” Much
f the knowledge of adrenergic receptors is based on
reclinical studies and in vitro studies, and there are signif-
cant species differences. It is crucial to obtain human data as
he best “model system” to understand the role and regula-
ion of alpha-AR in human coronary arteries.
iomarkers
lthough troponin assays have markedly improved the
iagnosis of MI, the time lag between presentation and the
ise in troponin levels leads to possible delays in diagnosis.
eichlin et al. (185), in a study of 487 consecutive patients
resenting to the emergency department with possible MI,
xamined the incremental value of a novel marker of
opeptin, the C-terminal part of the vasopressin prohor-
one. They found that the combination of troponin T and
opeptin measured at presentation improved the diagnosis
f MI, with an area under the receiver-operating character-
stic curve of 0.97, compared with 0.86 for troponin T alone
p  0.001).
Surveillance of with timing of surgery in mitral regurgi-
ation patients remains challenging. Pizarro et al. (186)
emonstrated in prospective fashion that in patients with
evere asymptomatic mitral regurgitation with normal ejec-
ion fractions, a cut point of B-type natriuretic peptide
BNP) at 105 pg/ml could discriminate a subgroup of
atients at higher risk of unsatisfactory outcome after
urgery. In an accompanying editorial, McCullough and
anzel (187) suggest that a change in BNP is probably the
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Highlights From JACC 2009 January 26, 2010:380–407rst clinical signal, prior to symptoms or echo alterations,
hat will herald near-term higher risk.
Although natriuretic peptide (NP) testing has shown
reat value in diagnosing heart failure in adults, it has not
een well studied in the neonate and pediatric population.
aw et al. (188) studied subjects in the acute care setting
ho had possible heart failure. A BNP of 170 pg/ml yielded
sensitivity of 94% and a specificity of 73% in the neonatal
roup, and 87% and 70% in the older group using a BNP of
1 pg/ml. In the accompanying editorial, Socrates et al.
189) felt that BNP testing may have a great future as a
ossible tool in adding details to the picture of the pediatric
eart failure patient.
The role of NPs in surgical patients are not well estab-
ished. To this end, Karthikeyan et al. (190) found clear
vidence for the association between pre-operative elevated
evels of NPs and post-operative occurrence of MACE in
oncardiac surgery patients. In an accompanying editorial,
olliger et al. (191) believe that future studies will be needed
o fully evaluate whether specific NP-based treatment mod-
fications will result in improved outcomes of surgical
atients.
It has not been well known that NPs are lipolytic and
low gastric emptying and absorption. Adiponectin, a 244–
mino acid peptide is also emerging as an important
egulator of metabolism. Tsukamoto et al. (192) demon-
trated that both atrial natriuretic peptide (ANP) and BNP,
ia the cyclic GMP pathway, increase adiponectin mRNA
xpression and increase adiponectin secretion from cultured
dipocytes. The authors have speculated that in the setting
f heart failure, adiponectin secretion may occur so as to
ttenuate the chronic energy deprivation the heart faces as it
witches from predominantly fatty acid oxidation to glucose
xidation. Also, the NP-induced lipolysis and adiponectin
ecretion could aid in weight loss, a potential unloading
ituation for the heart.
NPs have also been utilized as a surrogate for clinical
ongestion in patients hospitalized for acute heart failure.
ohen-Solal et al. (193), in a retrospective analysis of the
URVIVE (SURVival of patients with acute heart failure in
eed of Intra-VEnous inotropic support) trial, demon-
trated that patients admitted with heart failure who had
ecreases in BNP 30% over 5 days of hospitalization had
31-day risk reduction of all-cause mortality of 67% and a
80-day risk reduction of 47%. The results demonstrate that
arly lowering of BNP predicts both short- and long-term
ortality risks; this suggests that BNP reduction may serve
s a suitable prognostic marker of all-cause mortality.
McKie et al. (194) reported the biological properties of a
utant ANP identified in association with a familial form
f atrial fibrillation. This mutant form activates cGMP in
itro and exerts greater and more sustained natriuretic,
iuretic, glomerular filtration rate, and renal blood flow than
ative ANP. In an accompanying editorial, de Bold (195)
oints out that studies such as this suggest strategies to Tmprove upon the biological potency or the half-life of the
ormone for therapeutic purposes in cardiorenal disease.
Although troponin levels have been used to estimate
rognosis in heart failure, most studies involving hospital-
zed patients have used single measurements. Miller et al.
196) studied 172 ambulatory New York Heart Association
unctional class III to VI patients with serial cardiac tropo-
in T (cTnT) measurements every 3 months over a 2-year
eriod. The primary end point was death or cardiac trans-
lantation. Elevations of cTnT levels, using a threshold of
.01 ng/ml, in ambulatory HF patients was associated with
ncreased risk of events, especially if the cTnT elevations
ere persistently 0.01 ng/ml. Thus, this study suggests
hat serial measurements of troponin in ambulatory HF
atients may add to risk assessment.
Venge et al. (197) was one of the first to evaluate the
nalytical and clinical performance of a new sensitive tro-
onin I assay (Beckman Coulter). They found the 99th
ercentile cutoff of 0.01 g/l. Using this assay, they found a
ensitivity of 85% and a specificity of 90% in discriminating
ealthy subjects from those with ACS. In an accompanying
ditorial, Hollander (198) points out that although the
ncreased sensitivity will help rule in more patients in
uicker fashion, these lower cut points are likely to decrease
pecificity, possibly contributing to overcrowding of inten-
ive care unit and telemetry beds.
There have been little data regarding relative prognostic
alue during the time course of ACS. Eggers et al. (199)
easured a panel of biomarkers at randomization, 6 weeks,
nd 6 months for 5-year outcomes of death and MI.
aradoxical to some earlier data, only NT-proBNP level at
weeks added significant prognostic information to statis-
ical models containing conventional risk indicators.
enomics/Genetics
cDermott and Lloyd-Jones (200) provide a current and
linically relevant update of the role of biomarkers and
enetics in PAD. The effects of statin therapy on elevated
-reactive protein and all-cause mortality in patients
ith PAD suggest that the protective effect of statins is
rimarily in individuals with high C-reactive protein
evels. Understanding the fraction of PAD that is heri-
able is important for assessing the risk of family mem-
ers developing PAD and building in prevention strate-
ies early in clinical care. McDermott and Lloyd-Jones
200) estimate the genetic heritability of PAD to be
etween 22% and 48% after adjusting for cardiovascular
isk factors. The number of genetic markers discovered
or PAD have lagged behind those for stroke and other
omplex cardiovascular diseases. Two loci are reviewed
hat have met genome-wide significance, one on chro-
osome 1p and the other on chromosome 15q24
200,201). Replication in additional cohorts and testing
ith additional intermediate phenotypes are next steps.
he region on chromosome 15q24 is intriguing, as it
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January 26, 2010:380–407 Highlights From JACC 2009ontains a cluster of nicotinic acetylcholine receptors,
utations that are associated with increased risk of PAD in
mokers, as well as smoking quantity, nicotine dependence,
nd lung cancer (202).
Two articles were published in which unique mutations
n 1 gene were associated with both hypertrophic cardio-
yopathy and dilated cardiomyopathy (203,204). This gene
s cardiac ankyrin repeat domain 1 (ANKRD1). Arimura et
l. (203) identified 3 missense mutations in ANKRD1 in 3
nrelated individuals with hypertrophic cardiomyopathy.
oulik et al. (204) demonstrated that a distinct set of
utations in ANKRD1 were associated with dilated car-
iomyopathy. Testing for cosegregation of these individual
utations with disease in family members in additional
opulations will be helpful for further clarifying the role of
NKDR1 in heart disease and development. Unique mu-
ations in the same gene leading to different phenotypes is
eferred to as “phenotypic heterogeneity.” Past examples and
lengthier description of phenotypic heterogeneity is de-
cribed in an editorial by Mestroni et al. (205) that accom-
anied the back-to-back papers on ANKRD1 in JACC. The
bility to identify distinct mutations in a single gene
ssociated with multiple clinical phenotypes is likely to
ncrease as technology continues to improve.
It is estimated that nearly 30% of children exhibit cardiac
ysfunction within 10 years after cardiac transplantation,
ccounting for up to 20% of deaths (206). Auerbach et al.
206) reported that mutations in the renin-angiotensin-
ldosterone system (RAAS) in a transplant recipient are
ssociated with higher risks of rejection, graft cytokine
xpression, graft dysfunction, and higher mortality in pedi-
tric patients following cardiac transplantation. These find-
ngs suggest that in the setting of pediatric cardiac transplan-
ation, genotype can be used to help risk stratify patients and
otentially tailor clinical monitoring and treatment.
Finally, Margulies et al. (207) capture how genetics and
enomics are providing new insight into mechanisms of
eart failure. This review outlines key new terminology and
ighlights an update of disease-susceptibility genes for heart
ailure. A succinct discussion of epigenetics, alternative
RNA splicing, and microRNA is provided along with
pecific examples in the setting of heart failure. A number of
ecent articles have been written in the past year providing
vidence for microRNAs in heart and vascular development
nd disease. Finally, this review by Margulies et al. (207)
rovides the clinician with an update of how genetics and
enomics are currently being used diagnostically in the
linic.
Genetic variants have been shown to predict the likeli-
ood only of rhabdomyolysis following administration of
igh-dose simvastatin (80 mg), but little is known about the
ffect of these variants on the toxicity of other statins, or on
he more common problem of troublesome myalgias. Voora
t al. (208) demonstrate that the reduced function
LCO1B1*5 allele is associated with adverse muscle side
ffects for 3 other statins, including the problem of muscle wain without frank rhabdomyolysis. These findings partially
xplain the basis for statin intolerance, a common clinical
roblem.
Wang et al. (209) describe a genetic variation associated
ith control of the circulation and development of hyper-
ension. These findings demonstrate a novel pathophysio-
ogical link between the NPY1R locus and blood pressure,
hich may yield new approaches to understanding the
echanism and management of hypertension. Eventually,
hese findings may yield new drug targets for BP control.
ongenital Heart Disease
omenah et al. (210) present extensions of pulmonary valve
mplantation techniques developed for patients with en-
arged RV outflow tracts after patching. They studied 13
atients with a mean age of 14.3 years who had either
runcus arteriosus repair of pulmonary atresia (PA), tetral-
gy repair, or other complex heart disease. They deployed
tents in the RV outflow tract’s narrowest diameter, which
xtended above and below that narrowed area. Stents were
re-mounted on a 22 40-mm balloon catheter and dilated
n place, after which a double-balloon method was used for
lacement of the 22-mm Melody valve within the stent.
All of these patients had had residual obstruction as well
s insufficiency, and relief of the obstructive component was
videnced by RV pressure dropping from 61 to 37 mm Hg,
eduction in gradient from 39.6 to 12.2, a rise in pulmonary
iastolic pressure, and significant reduction in the degree of
ulmonary regurgitation to no more than a mild grade in
ny patient. The study suggests that pre-stenting allows
ulmonary valve implantation, avoiding the need to redo
urgical procedures in patients with tetralogy of Fallot repair
nd RV outflow patch. Further follow-up is, of course,
equired.
The collaborative study by Beca et al. (211) explored the
ssue of pre-operative brain injury in newborn infants, which
ay occur in utero or before their corrective surgery. The
pecific issue relates to previous studies reported by Mc-
uillen et al. (212), which suggested that those infants who
ad a balloon atrial septostomy were more likely to have
rain abnormalities, particularly white matter injury, not
pecifically ischemic stroke. This 2-center study included 64
nfants (44 with transposition, 13 with hypoplastic left
eart, and 7 with PA). Thirty-three of the babies had
alloon atrial septostomy: 25 were transposition and intact
entricular septum, and 8 with a ventricular septal defect as
ell. Brain injury occurred as white matter injury with
imilar incidence in transposition of the great arteries
TGA), hypoplastic left heart syndrome, and PA: 27%,
3%, and 29%, respectively. Stroke occurred in 3 infants, 3%
f those with balloon atrial septostomy, 9% of those who did
ot have balloon atrial septostomy. There were 4 important
ndings in the study. Brain injury was present in 30% of the
atients; there was a similar rate in the lesions; the pattern
as characteristically white matter injury; and there was no
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njury in patients with TGA. An important editorial com-
ent by Mosca (213) points out that the present study
efutes the findings of McQuillen et al. (212). The Beca et
l. (211) study shows predominantly white matter injury,
ith strokes being uncommon, and no association of injury
elated specifically to balloon atrial septostomy. Unfortu-
ately, neither study performed MRI scans before the
alloon septostomy.
Another paper in Circulation by Petit et al. (214) from the
hildren’s Hospital of Philadelphia had the same findings
hat both the degree of oxygenation and the time to surgery
ere major determinants of brain injury and must be held in
erspective. Also, Cheng (215) again pointed out a 10%
ncidence of perioperative stroke—a different type of abnor-
ality—half of which were present pre-operatively and
oint to the need for asking questions: whether fetal
iagnosis and maternal care might impact birth weight and
itigate this risk.
Two papers on aortopathy in congenital heart disease
atients and an editorial comment appeared this year in
ACC. The paper by Biner et al. (216) examined the
revalence of aortic dilation and abnormal elastic properties
n first degree relatives of patients with bicuspid aortic valve.
his relationship to genetic determinants is also examined
n an invited editorial comment by Silberbach (217). The
tudy reports that 32% of bicuspid aortic valve patients who
id not have aortic valve abnormalities had abnormal aortic
oot, annulus, and sinus dimensions significantly larger than
he controls, and found that elastic aortic root properties
ncluding distensibility and stiffness index are also present in
he first-degree relatives.
Similar studies by Loscalzo et al. (218) reported aortic
bnormalities and aortic dilation in 35% families of patients
ith coronary aortic dissections or rupture, suggesting that
hese are independent manifestations of a genetic disorder.
iner and colleagues admit to the limitation that the
rst-degree relatives were identified from patients at referral
enters who had advanced valvular and aortic disease, since
hese relatives were more willing to be studied.
In a paper invited before the 2 papers just discussed and
ublished the week before, Yetman and Graham (219)
iscuss the dilated aorta in patients with congenital heart
isease, adding insights of some of the febrilin abnormalities
n Marfan aortopathies, the role of proteolytic enzymes and
issue inhibitors of metalloproteinases as well as TGF-beta,
superfamily of cytokines that is important for maintenance
f vascular health on embryogenesis.They point out that the
pectrum of aortic impairment not only extends to families
ith bicuspid aortic valves, but has been found with greater
revalence in patients with Turner’s syndrome. The pro-
ensity for similar changes and risk of aortic rupture exists
n patients with coarctation and the abnormal aortic dilation
nd abnormalities of aortic physiology both in tetralogy of
allot patients and those with dextro-TGA involving dila-ion of the neo-aortic. They also point out that aortic and pulmonary dissection have occurred in unrepaired truncus
rteriosus, aorticopulmonary window, and ductus arteriosus.
he large cohort with congenital heart disease and aortic
athology surviving to adulthood will make this a major area
n which multicenter trials of medical therapies to prevent
rogressive aortic pathology in patients with CHD-related
ortopathy.
An important multicenter study on pediatric nonpost-
perative junctional ectopic tachycardia (JET), medical
anagement, and interventional therapies was presented by
ollins et al. (220). Ninety-four patients with JET and 5
atients with accelerated junctional rhythm, with a mean
ge of 0.8 years (range fetus to 16 years) were identified.
hose presenting at 6 months of age were likely to have
aster JET rates and incessant JET. These are truly sick
oungsters who presented with either fetal tachycardia with
r without hydrops, heart failure, rapid regular rates, and
yncope. Presentation was more likely to be incessant in
hose 6 months of age. Median JET was 209 beats/min,
ith rates as high as 320 beats/min, tending to be higher in
he younger patients. Successful treatment was most com-
on with amiodarone. Additional treatment strategies in-
luded radiofrequency ablation or cryoablation in 17 and 27
atients, respectively, with success rates of 82% and 85%,
nd pacemaker implant in 14%. The 4 deaths all occurred in
atients 6 months old. Comorbidities included prematu-
ity, possible myocarditis, the need for extracorporeal mem-
rane oxygenation (ECMO), and short gut syndrome from
rrest bowel ischemia. This international multicenter study
ocuments outcomes of patients with a difficult-to-treat
bnormality, especially dangerous and difficult in smaller
atients, and shows improved outcomes with a combination
f currently available.
An important international study by Spazzolini et al.
221) reported on the severe clinical manifestations of
QTS in infants. A worrisome and important subpopula-
ion of infants was identified: 20 who died suddenly and 16
ho had an acute cardiac event, 34 who experience syncope,
s well as a group of 3,253 who were asymptomatic. Forty
ercent of the patients were female, all of whom had a
orrected QT (QTc) interval of 500 ms. Four of the 20
nfants with sudden cardiac death had had a prior event, 4
f them were receiving beta-blockers. While small, this is a
ery high-risk group. In a helpful and important editorial
omment, Triedman (222) points out that the long QT
enotypes in infants might differ substantially from those
bserved in older patients. He also points out that screening
ad potentially diluted the phenotypic severity, since a wider
opulation base would show patients with milder forms of
ong QT interval as now fallen into our understanding of
he population. For the sickest patients, the administration
f beta-blockade was not associated with a survival benefit.
owever, as the population becomes diluted, evidence for
eta-blocker efficacy will continue to be acquired in patients
ith the milder spectrum of the disease. Currently, it is cost
rohibitive to routinely genotype newborns, but it is advis-
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Opotowsky et al. (223) performed hospital national
npatient sampling to identify adults over 18 years of age
dmitted with diagnostic codes related to congenital heart
isease. The number of hospitalizations from 1998 to 2005
oubled, including both simple and complex forms of heart
isease. The complex heart disease category increased by
0%, and total charges related to adult congenital heart
ervices increased by 127% compared with national total
ospital charges of only 66%. Thus, care for adult congen-
tal heart disease is claiming an increasing proportion of
ospital resources and health care providers in all spe-
ialties will likely encounter these complex patients with
ncreased frequency— emphasizing the need for cardiolo-
ists with specialized adult CHD training to care for this
urgeoning population.
ACC White Papers
new format introduced into JACC this year is “JACC
hite Papers.” Short consensus statements by experts
egarding commonly encountered clinical issues for which
o definitive evidence existed from research studies. These
hite Papers are not guidelines comparable to those issued
y the ACC or AHA, but are meant to provide some useful
ontext for dealing with these issues, given the existing data.
The first White Paper published in JACC dealt with the
pplication of CMR in patients with known or suspected
yocarditis (224). Friedrich et al. (224) discuss the multiple
iagnostic approaches to myocarditis and their limitations,
nd then review the published data regarding the applica-
ion of magnetic resonance in this disorder including the
etection of functional abnormalities, pericardial effusion,
orphologic abnormalities, tissue characterization, and ne-
rosis or fibrosis. They propose a comprehensive use of a
agnetic resonance criteria to both diagnose and follow
atients with myocarditis.
A challenging problem often encountered clinically is the
atient requiring triple anticoagulant therapy including
spirin, clopidogrel, and warfarin. Such patients typically
equire intracardiac stents in the setting of AF or prosthetic
alves, etc. In the absence of definitive data from the
andomized clinical trials, Holmes and colleagues address
he existing data and how they might be applied to current
ecision-making (225). The document prepared by the
riting group recognizes the increased bleeding risk inher-
nt in the use of triple anticoagulant therapy, and that this
isk increases with time. Therefore, they advocate the
onsideration of measures such as the use of their metal
tents to minimize the duration that triple anticoagulant
herapy would be required. For those patients in whom
riple therapy is clearly felt to be best, they recommend
ose-dose (100 mg) aspirin, conventional dose (75-mg
lopidogrel) and an international normalized ratio (INR)
arget close to 2.0.Another common clinical dilemma encountered by phy-
icians is the management of a patient receiving dual
ntiplatelet therapy in whom endoscopic gastrointestinal
rocedures are to be undertaken. Such patients will nearly
lways have a very well-established reason for the dual
ntiplatelet therapy, and it is clear that the sudden cessation
f such therapy, particularly in the first 6 months after
rocedure, can present a significant risk of acute ST in
atients who have received these devices. Although the
ardiovascular complications of endoscopic procedures are
ery infrequent, bleeding is a significant consideration. In a
ACC White Paper, Becker et al. (226) review all the data
hat currently exist that can be brought to bear on decisions
n this setting. They recommend that all elective endoscopic
rocedures be deferred for up to 12 months following PCI
nd DES placement. For those gastrointestinal procedures
hat must be undertaken, and which impose significant
leeding risk, it is recommended that the thienopyridine be
iscontinued 5 to 7 days before the gastrointestinal proce-
ure, that aspirin be continued, and that the patient be
estored as soon as possible.
eprint requests and correspondence: Dr. Anthony N. De-
aria, Cardiology Division, UCSD Medical Center, 200 West
rbor Drive, San Diego, California 92103-8411.
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